var title_f33_47_34544="PDA pulsed Doppler echo III";
var content_f33_47_34544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Pulsed Doppler tracing  in a patient with patent ductus arteriosus and left-to-right shunting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulsed Doppler tracing in a patient with&nbsp;a patent ductus arteriosus and significant left-to-right shunt was obtained by positioning sample volume in the descending thoracic aorta, proximal to the patent ductus arteriosus. Note the continuous run-off pattern of flow during diastole (arrows, lower panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34544=[""].join("\n");
var outline_f33_47_34544=null;
var title_f33_47_34545="Gram stain stool 1A with answer";
var content_f33_47_34545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62098%7EID%2F72909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62098%7EID%2F72909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Campylobacter jejuni in stool: Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of stool (x1000) can, in some cases, show Campylobacter jejuni, which are small, faint Gram negative curved rods which may be gull-winged in shape. This finding may provide presumptive evidence of Campylobacter infection prior to the results of stool culture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Campylobacter jejuni on CAMPY-agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isolation of Campylobacter jejuni from stool is best accomplished by use of CAMPY-agar, which contains several antibiotics to inhibit normal stool flora. Cultures are incubated at 42&ordm;C in a microaerophilic environment for 48 to 72 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34545=[""].join("\n");
var outline_f33_47_34545=null;
var title_f33_47_34546="UGI-SMA syndrome I";
var content_f33_47_34546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74949%7EGAST%2F56017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74949%7EGAST%2F56017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper gastrointestinal contrast study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This upper gastrointestinal contrast study (UGI) in an oblique projection demonstrates filling of the stomach and proximal duodenum with contrast (left side of photograph). Distal to this (dark arrowhead), there is compression of the third portion of the duodenum with only a scant amount of contrast in this region. This patient had repair of his scoliosis as evidenced by the hardware (right side of photograph).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    UGI dilated stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is the UGI study on the same patient demonstrating the dilated stomach (open arrowhead) and a dilated proximal duodenum (closed arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34546=[""].join("\n");
var outline_f33_47_34546=null;
var title_f33_47_34547="M mode echocardiography LV hypertrophy";
var content_f33_47_34547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Symmetric and asymmetric left ventricular hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 180px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M mode echocardiograms contrasting normal left ventricle (LV) (panel A), mild symmetric left ventricular hypertrophy (panel B) and marked asymmetric hypertrophy (panel C). The A wave from atrial contraction, or presystolic ventricular filling, is more exaggerated in mild left ventricular hypertrophy; exaggerated filling during the atrial phase of diastole can be a clue to decreased compliance, which may be more marked for the degree of hypertrophy.",
"    <div class=\"footnotes\">",
"     IVS: interventricular septum.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34547=[""].join("\n");
var outline_f33_47_34547=null;
var title_f33_47_34548="Enflurane: Drug information";
var content_f33_47_34548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enflurane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/57/8084?source=see_link\">",
"    see \"Enflurane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Compound 347&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      General Anesthetic, Inhalation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     Inhalation: Minimum alveolar concentration (MAC), the concentration at which 50% of patients do not respond to surgical incision, is 1.6% for enflurane. The concentration at which amnesia and loss of awareness occur (MAC - awake) is 0.4% for enflurane.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 0.5% to 3% (maximum concentration: 3%)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. MAC is reduced in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, for inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compound 347&trade;: &gt; 99.9% (250 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F164925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Via enflurane-specific calibrated vaporizers",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance of general anesthesia",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use for induction of general anesthesia is an FDA-labeled indication; however, it is not recommended clinically due to its irritant properties and unpleasant odor which causes breath-holding and coughing. In addition, other labeled indications that are not routinely used and/or recommended clinically include use as analgesia during vaginal delivery and use as an adjunct to other general anesthetic agents during Cesarean section delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F164968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Enflurane may be confused with isoflurane",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential safety issues exist for occupational exposure to inhaled anesthetic gases (primarily nitrous oxide). Although there are no documented adverse effects of chronic occupational exposure to halogenated anesthetic vapors, like enflurane, some epidemiological studies suggest a link between these anesthetics and increased health problems (particularly spontaneous abortion). No conclusive relationship has been determined, but the National Institute for Occupational Safety and Health Administration (NIOSH) recommends no worker be exposed to &gt;2 ppm (ceiling concentrations) over a period of 1 hour. Precautions (eg, adequate ventilation, scavenging-systems, minimizing leaks/spills) can help to lessen any potential risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, hypotension, myocardial depression, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Mood changes (may persist for several days after administration), cognitive function decreased (may persist for &le;3 days after administration), seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia (perioperative)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic injury, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory depression/arrest, hypoxemia, breath holding, cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Malignant hyperthermia, shivering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Cardiac arrest, hepatic failure (rare), hepatic necrosis (rare), nephrotoxicity, renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enflurane, other halogenated anesthetics, or any component of the formulation; known or suspected genetic susceptibility to malignant hyperthermia; seizure disorder",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Decrease in blood pressure is dose dependent, primarily due to peripheral vasodilation. May produce coronary steal (due to coronary vasodilation) and reflex tachycardia, but does not depress cardiac conduction nor does it sensitize the myocardium to catecholamine-induced arrhythmias like halothane (not available in U.S.).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased blood flow: May cause decrease in hepatic, renal and splenic blood flow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis: Postoperative hepatic dysfunction and hepatitis have rarely been reported. Postmarketing reports of hepatic failure and necrosis have also been rarely associated with enflurane.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Use of inhaled anesthetics has been associated with rare cases of perioperative hyperkalemia; concomitant use of succinylcholine was associated with many of the reported cases, but not all. Risk of hyperkalemia is increased in pediatric patients with underlying neuromuscular disease (eg, Duchenne muscular dystrophy). Other abnormalities may include elevation in CPK and myoglobinuria. Monitor closely for hyperkalemic associated arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Dilates the cerebral vasculature and may, in certain conditions, increase intracranial pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignant hyperthermia: May trigger malignant hyperthermia; avoid use in patients susceptible to malignant hyperthermia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: Respiration is depressed with a PaCO",
"     <sub>",
"      2",
"     </sub>",
"     of 55 mm Hg at 1 MAC. Hypoxic pulmonary vasoconstriction is blunted. Hypoxia induced increase in ventilation is abolished at low concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Contraindicated in patients with a history of seizure disorders; EEG seizure complexes have been seen with higher doses especially associated with hypocarbia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2E1 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Moderate): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Strong): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOPamine: Inhalational Anesthetics may enhance the arrhythmogenic effect of DOPamine.  Management: Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics.  If concomitant treatment cannot be avoided, monitor for arrhythmia.  Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Nasal): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Systemic, Oral Inhalation): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoproterenol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Isoproterenol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the hypertensive effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Inhalational Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norepinephrine: Inhalational Anesthetics may enhance the arrhythmogenic effect of Norepinephrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13396756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13396757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13396758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F164921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate and rhythm, temperature, oxygen saturation, end-tidal CO",
"     <sub>",
"      2",
"     </sub>",
"     and end-tidal enflurane concentrations should be monitored prior to and throughout anesthesia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alyrane (AU, BE, DK, KP, LU, NO, ZA);",
"     </li>",
"     <li>",
"      Compound 347 (ID, KP);",
"     </li>",
"     <li>",
"      Efrane (FI, NO, SE);",
"     </li>",
"     <li>",
"      Endurane (PH);",
"     </li>",
"     <li>",
"      Enfluran (CH);",
"     </li>",
"     <li>",
"      Enforan (AR);",
"     </li>",
"     <li>",
"      Enfran (MX);",
"     </li>",
"     <li>",
"      Ethrane (AT, AU, BE, CH, CL, DE, IE, IL, IT, LU, MY, NL, PH, PK, RU, TR, UY, VE);",
"     </li>",
"     <li>",
"      Etrane (BR);",
"     </li>",
"     <li>",
"      Gerolan (KP);",
"     </li>",
"     <li>",
"      Inhelthran (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 7-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Emergence time: Depends on blood concentration when enflurane is discontinued",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily as unmetabolized exhaled gases",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Campagna JA, Miller KW, and Forman SA, &ldquo;Mechanisms of Action of Inhaled Anesthetics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(21):2110-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34548/abstract-text/12761368/pubmed\" id=\"12761368\" target=\"_blank\">",
"        12761368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cousins MJ, Greenstein LR, Hitt BA, et al, &ldquo;Metabolism and Renal Effects of Enflurane in Man,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1976, 44(1):44-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34548/abstract-text/1244774/pubmed\" id=\"1244774\" target=\"_blank\">",
"        1244774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gion H and Saidman LJ, &ldquo;The Minimum Alveolar Concentration of Enflurane in Man,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1971, 35(4):361-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34548/abstract-text/5114398/pubmed\" id=\"5114398\" target=\"_blank\">",
"        5114398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stachnik J, &ldquo;Inhaled Anesthetic Agents,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(7):623-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34548/abstract-text/16554286/pubmed\" id=\"16554286\" target=\"_blank\">",
"        16554286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8910 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34548=[""].join("\n");
var outline_f33_47_34548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164936\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164963\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164941\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164942\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822422\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822423\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164923\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164914\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164925\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164924\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164968\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164961\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164928\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164917\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164960\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164920\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13396756\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13396757\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13396758\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164921\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539851\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164927\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8910|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/57/8084?source=related_link\">",
"      Enflurane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_47_34549="Late transition tutorial";
var content_f33_47_34549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Late transition (clockwise rotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 140px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The R waves remain of low amplitude from lead V1 until lead V4 or V5, at which point there is transition to a tall R wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34549=[""].join("\n");
var outline_f33_47_34549=null;
var title_f33_47_34550="Surgical anatomy of the adrenal glands";
var content_f33_47_34550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical anatomy of the adrenal glands",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34550/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34550/contributors\">",
"     Sanziana Roman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34550/contributors\">",
"     Leslie Wu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34550/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34550/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34550/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34550/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/47/34550/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H29523661\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal glands are essential to normal physiologic functioning. Significant pathology requiring surgical intervention may result from hyperplasia, adenoma formation, or malignancy.",
"   </p>",
"   <p>",
"    Adrenal surgery often is the primary treatment modality for a multitude of adrenal conditions. As a result, a strong working knowledge of adrenal embryology and anatomy is essential. Adrenalectomy can be performed by open or laparoscopic techniques with use of various approaches (anterior, lateral, or posterior) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/1\">",
"     1",
"    </a>",
"    ]. Regardless of the operative approach, the surgeon must have a complete understanding of the anatomy of the adrenal gland to avoid injury to vital adjacent structures and organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review surgical anatomy of the adrenal glands. Surgical diseases of the adrenal gland, diagnosis, and treatment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16435?source=see_link\">",
"     \"Basic principles in the laboratory evaluation of adrenocortical function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link\">",
"     \"Treatment of pheochromocytoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H673816\">",
"    <span class=\"h1\">",
"     FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal glands are composed of two functionally distinct endocrine units, the adrenal cortex and medulla, contained within a single capsule (",
"    <a class=\"graphic graphic_figure graphicRef73022 \" href=\"mobipreview.htm?29/33/30239\">",
"     figure 1",
"    </a>",
"    ). Each has distinct embryologic, anatomic, histologic, and functional characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674036\">",
"    <span class=\"h2\">",
"     Adrenal cortex function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal cortex is divided into three functional zones (",
"    <a class=\"graphic graphic_figure graphicRef81480 \" href=\"mobipreview.htm?2/40/2696\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The zona glomerulosa secretes mineralocorticoids (aldosterone) which regulate sodium and potassium homeostasis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2376?source=see_link\">",
"       \"Chapter 6C: Aldosterone\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The zona fasciculata secretes glucocorticoids (most importantly, cortisol) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=see_link\">",
"       \"Adrenal steroid biosynthesis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The zona reticularis secretes sex steroids (primarily androgens) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=see_link\">",
"       \"Adrenal steroid biosynthesis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674092\">",
"    <span class=\"h2\">",
"     Adrenal medulla function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal medulla synthesizes and secretes catecholamines, which modulate the body's sympathetic response to stress. The synthesis of catecholamines from the amino acid tyrosine is localized in the cells of the adrenal medulla and the organ of Zuckerkandl, and is modulated by phenylethanolamine-N-methyltransferase (PNMT), an enzyme that converts L-norepinephrine to L-epinephrine. Because PNMT is limited exclusively to these cells, epinephrine-secreting tumors arise predominantly in the adrenal medulla and the organ of Zuckerkandl [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1144635\">",
"    <span class=\"h2\">",
"     Abnormal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocortical diseases are classified on the basis of whether there is hormone deficiency or excess. Disorders of adrenal hormone deficiency (eg, primary adrenal insufficiency, also known as Addison&rsquo;s disease) are not treated surgically. In contrast, many disorders of adrenal hormone excess do require surgical intervention, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign cortisol, aldosterone, or less commonly, androgen-secreting adenomas (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=see_link\">",
"       \"Treatment of adrenocortical adenomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pheochromocytoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link\">",
"       \"Treatment of pheochromocytoma in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=see_link\">",
"       \"Pheochromocytoma in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adrenal carcinoma (most secrete cortisol with or without androgens) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"       \"Treatment of adrenocortical carcinoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A rare type of Cushing&rsquo;s syndrome due to bilateral micronodular hyperplasia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=see_link\">",
"       \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of a functioning autonomous adenoma in one gland may produce atrophy in the other gland via negative feedback mechanisms. As an example, in Cushing&rsquo;s syndrome due to an adrenal adenoma, autonomous secretion of cortisol by the adenoma suppresses both corticotropin-releasing hormone (CRF) from the hypothalamus and adrenocorticotropic hormone (ACTH) from the pituitary, leading to a decrease in steroid synthesis and eventual atrophy of the remaining adrenal gland. Recovery of an intact hypothalamic-pituitary-adrenal (HPA) axis and a normal-sized remaining adrenal gland may take up to two years after unilateral adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. Similar principles apply to chronic glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of adrenocortical adenomas\", section on 'Cushing's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523668\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The embryological development of the adrenal glands gives insight into the formation of accessory or aberrant glands and the widespread distribution of chromaffin tissue in sites away from the adrenal medulla, which is important in the management of pheochromocytoma and paraganglioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/10\">",
"     10",
"    </a>",
"    ]. Both cortical and medullary elements appear between the fifth and sixth weeks of fetal growth.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Development of the adrenal cortex",
"      </strong>",
"      &ndash; The cortex is derived from mesothelial cells lying in the dorsal wall of the primitive coelom adjacent to the mesonephric tubules and gonadal ridges [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/11\">",
"       11",
"      </a>",
"      ]. By the eighth week of fetal development, these cortical elements have differentiated into a thin outer definitive cortex and a thick inner fetal cortex. The fetal cortex actively produces fetal steroids during gestation, but involutes rapidly after birth. Adrenocortical rests occur in up to 50 percent of newborn infants, but tend to atrophy and disappear in the early postpartum period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The development of adrenal zones occurs slowly after birth, in parallel with regression of the fetal cortex, and is not completed until late in the first year of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/5\">",
"       5",
"      </a>",
"      ]. The definitive cortex persists and develops into the functional adrenal cortex, with distinct zonae glomerulosa and fasciculata present at birth. The zona reticularis develops during the first year of life. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Development of the adrenal medulla",
"      </strong>",
"      &ndash; The adrenal medulla and sympathetic nervous system develop in concert. The medullary elements, the sympathogonia, migrate forward from both sides of the neurogenic crest to the paraaortic and paravertebral regions and along the adrenal vein toward the medial aspect of the developing adrenal fetal cortex.",
"      <br/>",
"      <br/>",
"      Most extra-adrenal chromaffin cells regress. However, some cells remain and form the organ of Zuckerkandl, which is located to the left of the aortic bifurcation near the origin of the inferior mesenteric artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1144772\">",
"    <span class=\"h2\">",
"     Extra-adrenal gland anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;True accessory adrenal glands, which contain both cortical and medullary tissue, are rare. Most extra-adrenal glands contain either cortical or medullary tissue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ectopic cortical tissue &ndash;",
"      </strong>",
"      Ectopic cortical tissue often occurs in the areolar tissue adjacent to the kidney or in the pelvis. This ectopic tissue is usually found in relation to the sympathetic plexus and along the path of migration of structures arising from the urogenital ridge: epididymis, vas deferens, ovarian pedicle, broad ligament of the uterus, or within the ovary or testis (",
"      <a class=\"graphic graphic_figure graphicRef66339 \" href=\"mobipreview.htm?4/1/4116\">",
"       figure 3",
"      </a>",
"      ). Adrenocortical tissue also may be found in locations that are not explained by normal migration patterns of fetal tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Ectopic medullary tissue &ndash;",
"      </strong>",
"      Extra-adrenal chromaffin tissue may persist at any location along the migration path of neural crest cells, along the abdominal aorta, in association with the para-aortic sympathetic chain, the retroperitoneal celiac plexus, and the urinary bladder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/11,13\">",
"       11,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Extra-adrenal pheochromocytomas and paragangliomas &ndash;",
"      </strong>",
"      Extra-adrenal chromaffin tumors are termed extra-adrenal pheochromocytomas, and are also known as paragangliomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/14\">",
"       14",
"      </a>",
"      ]. Extra-adrenal pheochromocytomas constitute 15 percent of adult and 30 percent of pediatric pheochromocytomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. They are situated most commonly in the organ of Zuckerkandl, which is the collection of paraganglia located anterolaterally to the distal abdominal aorta between the origin of the inferior mesenteric artery and the aortic bifurcation. The second most common location of extra-adrenal pheochromocytomas is at the left renal hilum. Extra-adrenal pheochromocytomas can be multiple and have also been reported in the neck, posterior chest, atrium, and bladder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/6,13\">",
"       6,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"       \"Clinical presentation and diagnosis of pheochromocytoma\"",
"      </a>",
"      .)",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523675\">",
"    <span class=\"h1\">",
"     SIZE AND LOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal gland is approximately one third the size of the kidney at birth. However, in the adult, the adrenal gland is only one thirtieth the size of the kidney. This change in proportional size is a reflection of renal growth as well as the involution of the fetal adrenal cortex after birth.",
"   </p>",
"   <p>",
"    At the onset of puberty, the gland is at its adult size and only increases slightly in weight over the course of adult life, with the exception of stress and pregnancy or the development of pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/4\">",
"     4",
"    </a>",
"    ]. A normal adrenal gland in an adult weighs approximately 4 to 6 grams. The left adrenal is larger and flatter than the right adrenal gland. The weight of each adrenal may increase by nearly 50 percent during times of stress and pregnancy. Pathologic glands may reach 700 grams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adrenal glands are retroperitoneal and are located on the superior medial aspect of the upper pole of each kidney (",
"    <a class=\"graphic graphic_figure graphicRef61177 \" href=\"mobipreview.htm?31/21/32081\">",
"     figure 4",
"    </a>",
"    ). Gerota's fascia and pararenal fat separate the adrenals from the ribs, the pleural reflection, and the subcostal, sacrospinalis, and latissimus dorsi muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/11\">",
"     11",
"    </a>",
"    ]. The adrenal glands often are not visible on direct inspection of the retroperitoneum and their identification requires careful dissection and mobilization of adjacent structures and surrounding fat.",
"   </p>",
"   <p>",
"    The normal adrenal cortex and medulla have different characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal adrenal cortex is dark yellow and has a firm consistency and finely granular surface, allowing it to be differentiated from surrounding adipose tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/8\">",
"       8",
"      </a>",
"      ]. The cortex composes 80 to 90 percent of the volume of a normal gland.",
"     </li>",
"     <li>",
"      The central medulla is red-brown and is enclosed completely by the adrenal cortex, except at the hilum. The medulla constitutes 10 to 20 percent of the volume of a normal gland.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523682\">",
"    <span class=\"h2\">",
"     Right adrenal gland location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right adrenal gland is pyramid-shaped (&ldquo;witch&rsquo;s hat&rdquo;) and lies above the upper pole of the right kidney, between the liver and the diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superiorly, the right adrenal gland abuts the bare area of the liver. Based on autopsy studies, nearly 10 percent of people develop hepatic-adrenal fusion as a result of loss of the fibrous tissue between the liver parenchyma and the cranial portion of the right adrenal gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/17\">",
"     17",
"    </a>",
"    ]. Less frequently, the adrenals are adherent to the kidney.",
"   </p>",
"   <p>",
"    The right adrenal gland has the following relationships to surrounding structures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ventral-lateral area of the right adrenal is overlapped by the peritoneum between the liver, kidney, and hepatic flexure of the colon.",
"     </li>",
"     <li>",
"      The ventral-medial region is behind the inferior vena cava, separating the gland from the epiploic foramen anteriorly and the third portion of the duodenum and pancreatic head posteriorly. The body of the pancreas separates the right adrenal from the lesser sac and stomach. The thin medial border is related to the right celiac ganglion and the right inferior phrenic artery.",
"     </li>",
"     <li>",
"      The right adrenal gland may reside partially within the upper portion of the right paracolic gutter if the inferior layer of the right triangular or coronary ligament is particularly high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523689\">",
"    <span class=\"h2\">",
"     Left adrenal gland location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left adrenal gland is found between the kidney and aorta, near the tail of the pancreas and the splenic artery. The left adrenal gland has the following relationships to surrounding structures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superior half of the anterior surface of the left adrenal gland is covered anteriorly by peritoneum of the lesser sac. This separates the gland from the cardia of the stomach and the posterior pole of the spleen. The avascular segment of the gastrocolic ligament commonly is divided during surgery on the left adrenal gland.",
"     </li>",
"     <li>",
"      There is no peritoneum inferiorly, where the gland contacts the pancreas and splenic artery. The transverse mesocolon attaches along the inferior border of the pancreas, and is retracted inferiorly and medially for operative exposure.",
"     </li>",
"     <li>",
"      The medial border is adjacent to the inferomedial left celiac ganglion and to the left inferior phrenic and left gastric arteries, which ascend on the left diaphragmatic crus.",
"     </li>",
"     <li>",
"      The ventral aspect of the left adrenal gland is attached to the dorsal viscera of the stomach and to the medial border of the spleen and the body of the pancreas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/2,11\">",
"       2,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both the splenic vein and artery are inferior to the left adrenal gland.",
"     </li>",
"     <li>",
"      The left adrenal gland is located anterior to the origin of the celiac trunk and is separated from the aorta by several millimeters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523696\">",
"    <span class=\"h1\">",
"     BLOOD SUPPLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood flow to the normal adrenal gland is approximately 10",
"    <span class=\"nowrap\">",
"     mL/minute.",
"    </span>",
"    The blood supply to both the cortex and medulla increases during periods of stress. ACTH produces an immediate increase in blood flow to the adrenals.",
"   </p>",
"   <p>",
"    Arterial and venous capillaries within the adrenal gland integrate the function of the cortex and medulla. Cortisol-rich effluent flows from the cortex to the medulla, where it stimulates of the synthesis and activity of the enzyme phenylethanolamine N-methyltransferase (PNMT), leading to the conversion of norepinephrine to epinephrine. Extra-adrenal chromaffin tissues lack this mechanism, thereby secreting mostly norepinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adrenal glands have a rich arterial supply from three main groups of inflow vessels (",
"    <a class=\"graphic graphic_figure graphicRef59684 \" href=\"mobipreview.htm?37/2/37927\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53746 \" href=\"mobipreview.htm?14/14/14566\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Superior suprarenal arteries",
"      </strong>",
"      &ndash; The superior suprarenal arteries are derived from the inferior phrenic arteries, which pass just superior and medial to the adrenal glands. Each inferior phrenic artery gives off a series of branches to the ipsilateral adrenal gland before it supplies the diaphragm.",
"     </li>",
"     <li>",
"      <strong>",
"       Middle suprarenal artery",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The middle suprarenal artery is derived from the aorta.",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       The inferior suprarenal renal arteries",
"      </strong>",
"      &ndash; The inferior suprarenal arteries are derived from the adjacent renal artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other adjacent vessels also may supply branches to the adrenal gland; these include the intercostal arteries, the left ovarian artery, and the left internal spermatic arteries. Because any arteries approaching the gland can branch and re-branch, the number of adjacent vessels entering it may be quite numerous. There is no constant position in which these arteries enter the gland. This anatomic detail is important because encountering these small vessels in the perirenal fat indicates proximity of the gland, and the feeding vessels will bleed unless cauterized or ligated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3317737\">",
"    <span class=\"h1\">",
"     VENOUS DRAINAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With rare exceptions, each adrenal gland has a single draining vein. Vascular control of the adrenal vein by the surgeon is easier on the left because the left adrenal vein is much longer than the right [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/8\">",
"     8",
"    </a>",
"    ]. On the right, the adrenal vein is less than 1 cm in length and empties directly into the posterior inferior vena cava, creating a risk for injury and hemorrhage during surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74898365\">",
"    <span class=\"h2\">",
"     Venous drainage left adrenal gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left adrenal vein emerges at the hilum of the gland and is approximately 2 to 3 cm in length. The length of the left adrenal vein permits ready vascular control during left adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The left adrenal (suprarenal) vein drains into either the left renal vein or the left inferior phrenic vein. The left adrenal vein passes inferomedially from the lower pole of the gland, receives the inferior phrenic vein, and follows an oblique downward course to enter the left renal vein. Occasionally, the left adrenal vein drains into the left inferior phrenic vein, which then empties into the left renal vein or crosses over the aorta to enter directly into the inferior vena cava.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3317563\">",
"    <span class=\"h2\">",
"     Venous drainage right adrenal gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right adrenal (suprarenal) vein emerges from the hilum and enters the posterior segment of the inferior vena cava at a 45&ordm; angle. The right adrenal vein often cannot be exposed until the gland is circumferentially mobilized because the vein is typically less than 1 cm in length.",
"   </p>",
"   <p>",
"    The origin of the right adrenal vein may be obscured by an enlarged gland or tumor. Additional smaller veins are found in 5 to 10 percent of right adrenal glands. Rarely, aberrant veins may drain into the right hepatic vein or right renal vein. In addition, small direct hepatic branches draining from the posterior aspect of the liver into the vena cava may join the adrenal vein and can be torn during adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523703\">",
"    <span class=\"h1\">",
"     LYMPHATIC DRAINAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal gland has two lymphatic plexuses: one in the medulla and one deep to the adrenal capsule.",
"   </p>",
"   <p>",
"    Most of the adrenal lymphatics terminate in the lateral aortic lymph nodes and the paraaortic nodes near the diaphragmatic crus and origin of the renal artery. Hence, when operating on a suspected malignant adrenal tumor, adjacent paraaortic and paracaval nodes must be evaluated for evidence of local metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The remaining lymphatics traverse the diaphragm and drain toward the thoracic duct or the posterior mediastinum, thus explaining the pattern of metastatic spread of malignant tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523710\">",
"    <span class=\"h1\">",
"     INNERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innervation of the adrenal glands is via visceral afferent fibers arising from the celiac, aorticorenal, and renal autonomic ganglia in the retroperitoneum (",
"    <a class=\"graphic graphic_figure graphicRef50507 \" href=\"mobipreview.htm?13/62/14309\">",
"     figure 7",
"    </a>",
"    ). These fibers connect with the posterior vagus nerve, phrenic nerve, and greater and lesser splanchnic nerves (",
"    <a class=\"graphic graphic_figure graphicRef71492 \" href=\"mobipreview.htm?11/23/11639\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The nerve fibers provide sensory or indirect vasomotor innervation as they traverse the adrenal cortex, and terminate in the medulla as preganglionic sympathetic fibers. The adrenal medulla is a postsynaptic sympathetic nerve and functions as a neuroendocrine transducer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34550/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29523724\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adrenal glands are essential to normal functioning, and significant pathology results from hyperplasia or neoplasia, or from primary or metastatic malignant adrenal tumors. (See",
"      <a class=\"local\" href=\"#H29523661\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The embryological development of the adrenal glands gives insight into the formation of accessory or aberrant glands and the widespread distribution of chromaffin tissue in sites away from the adrenal medulla along the paraortic chain, which is important in the consideration of pheochromocytoma and paraganglioma. (See",
"      <a class=\"local\" href=\"#H29523668\">",
"       'Embryology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The adrenal glands are retroperitoneal and are located on the superior medial aspect of the upper pole of each kidney. (See",
"      <a class=\"local\" href=\"#H29523675\">",
"       'Size and location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The adrenal glands have a rich, multiple arterial supply from three main groups of vessels: the superior suprarenal arteries, the middle suprarenal artery and the inferior suprarenal renal arteries. &nbsp;(See",
"      <a class=\"local\" href=\"#H29523696\">",
"       'Blood supply'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular control of the adrenal vein is more difficult on the right than the left because the right adrenal vein is less than a centimeter in length and empties directly into the posterior inferior vena cava, which creates a risk for injury and hemorrhage. (See",
"      <a class=\"local\" href=\"#H3317737\">",
"       'Venous drainage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/1\">",
"      Wells SA, Merke DP, Cutler GB Jr, et al. Therapeutic controversy: The role of laparoscopic surgery in adrenal disease. J Clin Endocrinol Metab 1998; 83:3041.",
"     </a>",
"    </li>",
"    <li>",
"     Perrier, ND, Boger, MS. Surgical anatomy. In: Adrenal Glands: Diagnostic Aspects and Surgical Therapy, Linos, D, van Heerden, JA (Eds), Springer, New York 2005. p.7.",
"    </li>",
"    <li>",
"     Surgical embryology and anatomy of the adrenal glands. In: Textbook of Endocrine Surgery, 2nd edition, Clark, OH, Duh, QY, Kebebew, E (Eds), Elsevier Saunders, Philadelphia 2005. p.557.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/4\">",
"      Bland ML, Desclozeaux M, Ingraham HA. Tissue growth and remodeling of the embryonic and adult adrenal gland. Ann N Y Acad Sci 2003; 995:59.",
"     </a>",
"    </li>",
"    <li>",
"     Brunt, LM, Halverson, JD. The Endocrine System. In: The Physiologic Basis of Surgery, O'Leary, JP (Eds), Lippincott, Philadelphia 2002. p.351.",
"    </li>",
"    <li>",
"     Gray, DG, Thompson, NW. Pheochromocytoma. In: Surgical Endocrinology, Doherty, GM, Skogseid, B (Eds), Lippincott, New York 2001. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/7\">",
"      Livett BG, Marley PD, Wan DC, Zhou XF. Peptide regulation of adrenal medullary function. J Neural Transm Suppl 1990; 29:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/8\">",
"      Avisse C, Marcus C, Patey M, et al. Surgical anatomy and embryology of the adrenal glands. Surg Clin North Am 2000; 80:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/9\">",
"      Doherty GM, Nieman LK, Cutler GB Jr, et al. Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing's syndrome. Surgery 1990; 108:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/10\">",
"      Donnellan WL. Surgical Anatomy of Adrenal Glands. Ann Surg 1961; 154:298.",
"     </a>",
"    </li>",
"    <li>",
"     Moore, KL, Dalley, AF. Clinically Oriented Anatomy, 4th edition, Lippincott, Baltimore 1999. p.279.",
"    </li>",
"    <li>",
"     Brunt, LM, Moley, J. The pituitary and adrenal glands. In: Sabiston Textbook of Surgery, 17th edition, Townsend, CM, Beauchamp, RD, Evers, BM, Mattox, KL (Eds), Saunders, Philadelphia 2004. p.1023.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/13\">",
"      Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/14\">",
"      Disick GI, Palese MA. Extra-adrenal pheochromocytoma: diagnosis and management. Curr Urol Rep 2007; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/15\">",
"      Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147:1.",
"     </a>",
"    </li>",
"    <li>",
"     Kebebew, E, Duh, QY. Operative strategies for adrenalectomy. In: Surgical Endocrinology, Doherty, GM, Skogseid, B (Eds), Lippincott, New York 2001. p.273.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34550/abstract/17\">",
"      Honma K. Adreno-hepatic fusion. An autopsy study. Zentralbl Pathol 1991; 137:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15053 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34550=[""].join("\n");
var outline_f33_47_34550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29523724\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29523661\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H673816\">",
"      FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H674036\">",
"      Adrenal cortex function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H674092\">",
"      Adrenal medulla function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1144635\">",
"      Abnormal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29523668\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1144772\">",
"      Extra-adrenal gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29523675\">",
"      SIZE AND LOCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29523682\">",
"      Right adrenal gland location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29523689\">",
"      Left adrenal gland location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29523696\">",
"      BLOOD SUPPLY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3317737\">",
"      VENOUS DRAINAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74898365\">",
"      Venous drainage left adrenal gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3317563\">",
"      Venous drainage right adrenal gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29523703\">",
"      LYMPHATIC DRAINAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29523710\">",
"      INNERVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29523724\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15053|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/33/30239\" title=\"figure 1\">",
"      Cross-sectional anatomy of the adrenal gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/40/2696\" title=\"figure 2\">",
"      Zones of adrenal tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/1/4116\" title=\"figure 3\">",
"      Development of the adreno-genital primordium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/21/32081\" title=\"figure 4\">",
"      Adrenal glands in relation to the kidneys and great vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/2/37927\" title=\"figure 5\">",
"      Adrenal blood supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/14/14566\" title=\"figure 6\">",
"      Blood supply of the adrenal glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/62/14309\" title=\"figure 7\">",
"      The autonomic ganglia in the retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/23/11639\" title=\"figure 8\">",
"      Innervation of the adrenal glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16435?source=related_link\">",
"      Basic principles in the laboratory evaluation of adrenocortical function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=related_link\">",
"      Treatment of adrenocortical adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_47_34551="Rituximab: Pediatric drug information";
var content_f33_47_34551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rituximab: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"    see \"Rituximab: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/3/15414?source=see_link\">",
"    see \"Rituximab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rituxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rituxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Monoclonal Antibody",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Monoclonal Antibody",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"      see \"Rituximab: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols. Pretreatment with acetaminophen and an antihistamine is recommended for all indications. For oncology uses, a uricostatic agent (eg, allopurinol) and aggressive hydration is recommended for patients at risk for tumor lysis syndrome (high tumor burden or lymphocytes &gt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). In patients with CLL,",
"     <i>",
"      pneumocystis jiroveci",
"     </i>",
"     pneumonia (PCP) and antiherpetic viral prophylaxis is recommended during treatment (and for up to 12 months following treatment). In patients with WG and MPA, PCP prophylaxis is recommended during and for 6 months after rituximab treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Autoimmune hemolytic anemia:",
"     </b>",
"     Infants &ge;4 months, Children, and Adolescents: I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 2-4 doses (Zecca, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chronic ITP:",
"     </b>",
"     Children and Adolescents: I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 4 doses (Parodi, 2009; Wang, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Post-transplant lymphoproliferative disorder:",
"     </b>",
"     Infants &ge;11 months, Children, and Adolescents: I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 3-4 doses (Milpied, 2000; Serinet, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Refractory SLE:",
"     </b>",
"     Children &ge;8 years and Adolescents: I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 2-4 doses; or 750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 15 (maximum dose: 1000 mg) (Marks, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Refractory severe nephrotic syndrome:",
"     </b>",
"     Infants &ge;11 months, Children, and Adolescents: I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 1-4 doses has been used in small case series, case reports, and retrospective analyses, including reports of successful remission induction of severe or refractory nephrotic syndromes that are poorly responsive to standard therapies (Della Strologo, 2009; Fujinaga, 2010; Gugonis, 2008; Kaito, 2010; Prytula, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      CLL:",
"     </b>",
"     I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on the day prior to fludarabine/cyclophosphamide in cycle 1, then 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 (every 28 days) of cycles 2-6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Granulomatosis with polyangiitis (GPA; Wegener&rsquo;s granulomatosis) and Microscopic polyangiitis (MPA):",
"     </b>",
"     I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 4 doses (in combination with methylprednisolone I.V. for 1-3 days followed by daily prednisone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      NHL (relapsed/refractory, low-grade or follicular CD20-positive, B-cell):",
"     </b>",
"     I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 4 or 8 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Retreatment following disease progression: I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      NHL (diffuse large B-cell):",
"     </b>",
"     I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     given on day 1 of each chemotherapy cycle for up to 8 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      NHL (follicular, CD20-positive, B-cell, previously untreated):",
"     </b>",
"     I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     given on day 1 of each chemotherapy cycle for up to 8 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy (as a single agent, in patients with partial or complete response to rituximab plus chemotherapy; begin 8 weeks after completion of combination chemotherapy): I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 weeks for 12 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      NHL (nonprogressing, low-grade, CD20-positive, B-cell, after first-line CVP)",
"     </b>",
"     : I.V. infusion: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 4 doses every 6 months for up to 4 cycles (initiate after 6-8 cycles of chemotherapy are completed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      NHL:",
"     </b>",
"     Combination therapy with ibritumomab: I.V. infusion: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V. day 1; repeat in 7-9 days with ibritumomab",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     I.V. infusion: 1000 mg on days 1 and 15 in combination with methotrexate; subsequent courses may be administered every 24 weeks (based on clinical evaluation), if necessary may be repeated no sooner than every 16 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with methylprednisolone 100 mg I.V. (or equivalent) is recommended 30 minutes prior to each dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rituxan&reg;: 10 mg/mL (10 mL, 50 mL) [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7882123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM169892.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM169892.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      DO NOT ADMINISTER UNDILUTED OR as an I.V. push or rapid injection:",
"     </b>",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Initial infusion: Start at a rate of 50 mg/hour at a final concentration for administration of 1-4 mg/mL in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W. If no hypersensitivity or infusion-related reactions occur, increase infusion rate in 50 mg/hour increments every 30 minutes to a maximum infusion rate of 400 mg/hour as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Subsequent infusions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Standard infusion rate: If patient tolerated initial infusion, start at 100 mg/hour and increased by 100 mg/hour increments at 30 minute intervals to a maximum infusion rate of 400 mg/hour. If hypersensitivity or infusion-related reactions occur, slow or interrupt the infusion. If symptoms completely resolve, resume infusion at 50% of the previous rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Accelerated infusion rate (90 minutes): For adult patients with previously untreated follicular NHL and diffuse large B-cell NHL who are receiving a corticosteroid as part of their combination chemotherapy regimen, have a circulating lymphocyte count &lt;5000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or have no significant cardiovascular disease. After tolerance has been established (no grade 3 or 4 infusion-related event) at the recommended infusion rate in cycle 1, a rapid infusion rate may be used beginning with cycle 2. The daily corticosteroid, acetaminophen, and diphenhydramine are administered prior to treatment, then the rituximab dose is administered over 90 minutes, with 20% of the dose administered over the first 30 minutes and the remaining 80% is given over 60 minutes (Sehn, 2007). If the 90-minute infusion in cycle 2 is tolerated, the same rate may be used for the remainder of the treatment regimen (through cycles 6 or 8).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11514605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze or shake; protect vials from direct sunlight; dilution of rituximab to a final concentration of 1-4 mg/mL in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W is stable for 24 hours if refrigerated or stored at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) [including relapsed or refractory, low-grade or follicular B-cell NHL (as a single agent); follicular B-cell NHL, previously untreated (in combination with first-line chemotherapy, and as single-agent maintenance therapy if response to first-line rituximab with chemotherapy); nonprogressing, low-grade B-cell NHL (as a single agent after first-line CVP treatment), diffuse large B-cell NHL, previously untreated (in combination with CHOP chemotherapy or other anthracycline-based regimen)]; treatment of CD20-positive chronic lymphocytic leukemia (CLL) (in combination with cyclophosphamide and fludarabine); treatment of moderately- to severely-active rheumatoid arthritis (in combination with methotrexate) in patients with inadequate response to one or more TNF antagonists; treatment of granulomatosis with polyangiitis (GPA; Wegener&rsquo;s Granulomatosis) and microscopic polyangiitis (MPA)  in combination with glucorticoids (FDA approved in adults); has also been used for the treatment of systemic autoimmune disorders (other than rheumatoid arthritis; ie, autoimmune hemolytic anemia in children); refractory systemic lupus erythematosus; steroid-refractory chronic graft-versus-host disease (GVHD); refractory nephrotic syndrome, chronic immune thrombocytopenic purpura (ITP); post-transplant lymphoproliferative disorder (PTLD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rituxan&reg; may be confused with Remicade&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       RiTUXimab may be confused with brentuximab, bevacizumab, inFLIXimab, ruxolitinib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The rituximab dose for rheumatoid arthritis is a flat dose (1000 mg) and is not based on body surface area (BSA).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F218875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients treated with rituximab for rheumatoid arthritis (RA) may experience fewer adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hyper-/hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, dizziness, fatigue, fever, headache, insomnia, migraine, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, nausea, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, cytopenia, lymphopenia, leukopenia, neutropenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle spasm, myalgia, neuropathy, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, epistaxis, rhinitis, sinusitis, throat irritation, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infusion-related reactions (may include angioedema, bronchospasm, chills, dizziness, fever, headache, hyper-/hypotension, myalgia, nausea, pruritus, rash, rigors, urticaria, and vomiting); infection (including bacterial, viral, fungal); night sweats;  human antichimeric antibody (HACA) positive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, anaphylactoid reaction/anaphylaxis, angina, aplastic anemia, ARDS, arrhythmia, bowel obstruction/perforation, bronchiolitis obliterans, cardiac failure, cardiogenic shock, encephalomyelitis, fatal infusion-related reactions, fulminant hepatitis, gastrointestinal perforation, hemolytic anemia, hepatic failure, hepatitis, hepatitis B reactivation, hyperviscosity syndrome (in Waldenstr&ouml;m&rsquo;s macroglobulinemia), hypogammaglobulinemia (prolonged), hypoxia, interstitial pneumonitis, laryngeal edema, lichenoid dermatitis, lupus-like syndrome, marrow hypoplasia, MI, mucositis, mucocutaneous reaction, neutropenia (late-onset occurring &gt;40 days after last dose), optic neuritis, pancytopenia (prolonged), paraneoplastic pemphigus (uncommon), pleuritis, pneumonia, pneumonitis, polyarticular arthritis, polymyositis, posterior reversible encephalopathy syndrome (PRES), progressive multifocal leukoencephalopathy (PML), pure red cell aplasia, renal toxicity, reversible posterior leukoencephalopathy syndrome (RPLS), serum sickness, Stevens-Johnson syndrome, supraventricular arrhythmia, systemic vasculitis, toxic epidermal necrolysis, tuberculosis reactivation, tumor lysis syndrome, uveitis, vasculitis with rash, ventricular fibrillation, ventricular tachycardia, vesiculobullous dermatitis, viral reactivation (includes JC virus, cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis C), wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rituximab or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing cardiac or pulmonary conditions, renal impairment, and patients at risk for developing tumor lysis syndrome. Patients should be brought up to date with all recommended immunizations before initiating therapy. Live vaccines should not be given concurrently; there are no data available concerning secondary transmission of live vaccines in patients receiving therapy; evaluate risks of therapy delay versus benefit (of inactivated vaccines) for NHL patients. Safety and efficacy of rituximab in combination with biologic agents or disease-modifying antirheumatic drugs (DMARD) other than methotrexate or for retreatment of RA have not been established. Rituximab is not recommended for use in RA patients who have not had prior inadequate response to TNF antagonists. The safety of concomitant immunosuppressants other than corticosteroids has not been evaluated in patients with WG or MPA after rituximab-induced B-cell depletion. There are only limited data on subsequent courses of rituximab for WG or MPA; safety and efficacy of retreatment has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Progressive multifocal leukoencephalopathy (PML) due to JC virus has been reported with rituximab use (may be fatal)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Cases were reported in patients with hematologic malignancies or autoimmune diseases receiving rituximab either with combination chemotherapy or with hematopoietic stem cell transplant. Cases were also reported in patients receiving rituximab for autoimmune disease and may have received concurrent or prior immunosuppressant therapy. Onset may be delayed, although most cases were diagnosed within 12 months of the last rituximab dose. Symptoms may include confusion/disorientation, motor weakness/hemiparesis, altered vision/speech, and poor motor coordination; may progress over weeks to months. Evaluate any neurological change promptly; discontinue rituximab in patients who develop PML; consider reduction/discontinuation of concurrent chemotherapy or immunosuppressants.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe (sometimes fatal) infusion reactions which may include hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, MI, ventricular fibrillation, cardiogenic shock, urticaria, and anaphylaxis have occurred within 24 hours of rituximab administration; monitor closely during infusion",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Most of these reactions occurred during the first infusion with time to onset of 30-120 minutes. Fatal infusion reactions were more frequently associated with female gender, pulmonary infiltrates, CLL, or mantle cell lymphoma. Close monitoring required during first and subsequent infusions, especially in patients with pre-existing cardiac and pulmonary conditions, patients with prior cardiopulmonary adverse events, and those with high numbers of circulating malignant cells (&ge;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). Prior to infusion, premedicate patients with acetaminophen and an antihistamine (and methylprednisolone for patients with RA). Medications for the treatment of hypersensitivity reactions (eg, bronchodilators, epinephrine, antihistamines, corticosteroids) should be available for immediate use. In the event of a severe reaction, interrupt the rituximab infusion and institute supportive care measures (eg, I.V. fluids, vasopressors, oxygen, bronchodilators, diphenhydramine, and acetaminophen). When symptoms completely resolve, may resume rituximab at a 50% reduction from the previous infusion rate. Discontinue rituximab with grades 3 or 4 infusion reactions or in the event of serious or life-threatening cardiac arrhythmias. Mild to moderate infusion-related reactions (eg, chills, fever, rigors) occur frequently in 80% of patients after first infusion, decreasing to 40% in subsequent infusions and are typically managed through slowing or interrupting the infusion; infusion may be resumed at a 50% infusion rate reduction upon resolution of symptoms. Due to the potential for hypotension, consider withholding antihypertensives 12 hours prior to treatment. Rheumatoid arthritis patients are at increased risk for cardiovascular events; monitor closely during and after each infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tumor lysis syndrome leading to acute renal failure requiring dialysis may occur 12-24 hours following the first dose when used as a single agent to treat NHL",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Hyperkalemia, hypocalcemia, hyperuricemia, and/or hyperphosphatemia may occur. Prophylaxis for tumor lysis syndrome (allopurinol and hydration) should be considered for patients at risk (patients with high tumor burden or with high numbers of circulating malignant cells). Monitor for signs of renal failure; discontinue rituximab with increasing serum creatinine or oliguria. Correct electrolyte abnormalities; monitor hydration status. May cause fatal renal toxicity in patients with hematologic malignancies. Patients who received combination therapy with cisplatin and rituximab for NHL experienced renal toxicity during clinical trials; this combination is not an approved treatment regimen. Severe and sometimes fatal mucocutaneous reactions (lichenoid dermatitis, paraneoplastic pemphigus, Stevens-Johnson syndrome, toxic epidermal necrolysis, and vesiculobullous dermatitis) have been reported, occurring from 1-13 weeks following exposure",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients experiencing severe mucocutaneous skin reactions should not receive further infusions and should seek prompt medical evaluation. Abdominal pain, bowel obstruction, and perforation have been reported (rarely fatal) with an average onset of symptoms of ~6 days; complaints of abdominal pain should be evaluated, especially if early in the treatment course.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Reactivation of hepatitis B (with fulminant hepatitis, hepatic failure, and death) has been reported in association with use; consider screening high-risk patients prior to therapy initiation. Do not use if severe active infection is present. Serious and potentially fatal bacterial, fungal, and either new or reactivated viral infections may occur during treatment and up to 1 year after completing rituximab. Infections have been observed in patients with prolonged hypogammoglobulinemia, defined as hypogammaglobulinemia &gt;11 months after rituximab exposure; monitor immunoglobulin levels as necessary. Associated new or reactivated viral infections have included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. Discontinue rituximab (and concomitant chemotherapy) in patients who develop viral hepatitis and initiate antiviral therapy. Discontinue rituximab in patients who develop other serious infections and initiate appropriate anti-infective treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2197621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: RiTUXimab may enhance the adverse/toxic effect of Abatacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: RiTUXimab may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: RiTUXimab may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated adverse effects including decreased (reversible) B-cells and immunosuppression. IgG molecules are known to cross the placenta (rituximab is an engineered IgG molecule) and rituximab has been detected in the serum of infants exposed in utero. B-Cell lymphocytopenia lasting &lt;6 months may occur in exposed infants. Retrospective case reports of inadvertent pregnancy during rituximab treatment (often combined with concomitant teratogenic therapies) describe premature births, and infant hematologic abnormalities and infections; no specific pattern of birth defects has been observed (limited data). Effective contraception should be used during and for 12 months following treatment. Healthcare providers are encouraged to enroll women with rheumatoid arthritis exposed to rituximab during pregnancy in the OTIS AutoImmune Diseases Study by contacting the Organization of Teratology Information Specialists (877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, CBC with differential and platelet counts (obtain at weekly to monthly intervals and more frequently in patients with cytopenias, or at 2-4 month intervals in rheumatoid arthritis patients, WG and MPA), serum electrolytes, uric acid, renal function tests, liver function tests, fluid balance; monitor for infusion reactions, cardiac monitoring for patients with pre-existing cardiac condition; peripheral CD20",
"     <sup>",
"      +",
"     </sup>",
"     cells; human antimurine antibody and human antichimeric antibody titers (high levels may increase the risk of allergic reactions); screening for hepatitis B, signs or symptoms of PML, signs or symptoms of bowel obstruction/perforation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rituximab is a monoclonal antibody directed against the CD20 antigen on B-lymphocytes. Rituximab binds to the antigen on the cell surface, activating complement-dependent cytotoxicity; binds to human Fc receptors mediating cell killing through an antibody-dependent cellular toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1049768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: B-cell recovery begins &sim;6 months following completion of treatment; medium B-cell levels return to normal by 12 months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Binds to lymphoid cells in the thymus, spleen, and B lymphocytes in peripheral blood and lymph nodes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NHL: Median terminal half-life: 22 days (range: 6-52 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CLL: Median terminal half-life: 32 days (range: 14-62 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatoid arthritis: 18 days (range: 5-78 days)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/3/15414?source=see_link\">",
"      see \"Rituximab: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, sore throat, rash, dizziness, chest pain, abdominal pain, yellowing of skin or eyes, feeling of weakness, bruising, bleeding, or shortness of breath occurs. Inform physician if you experience any new neurological signs or symptoms including major changes in vision, unusual movements, loss of balance or coordination, disorientation, or confusion. Advise individuals of childbearing potential to use effective contraceptive methods and avoid becoming pregnant during and for 12 months following treatment with rituximab.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chakravarty EF, Murray ER, Kelman A, et al, \"Pregnancy Outcomes After Maternal Exposure to Rituximab,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(5):1499-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/21098742/pubmed\" id=\"21098742\" target=\"_blank\">",
"        21098742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dello Strologo L, Guzzo I, Laurenzi C, et al, \"Use of Rituximab in Focal Glomerulosclerosis Relapses After Renal Transplantation,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2009, 88(3):417-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/19667947/pubmed\" id=\"19667947\" target=\"_blank\">",
"        19667947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards JC, Szczepanski L, Szechinski J, et al, \"Efficacy of B-Cell-Targeted Therapy With Rituximab in Patients With Rheumatoid Arthritis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(25):2572-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/15201414/pubmed\" id=\"15201414\" target=\"_blank\">",
"        15201414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fujinaga S, Hirano D, Nishizaki N, et al, \"Single Infusion of Rituximab for Persistent Steroid-Dependent Minimal-Change Nephrotic Syndrome After Long-Term Cyclosporine,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2010, 25(3):539-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/20049616/pubmed\" id=\"20049616\" target=\"_blank\">",
"        20049616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guigonis V, Dallocchio A, Baudouin V, et al, \"Rituximab Treatment for Severe Steroid- or Cyclosporine-Dependent Nephrotic Syndrome: A Multicentric Series of 22 Cases,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2008, 23(8):1269-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/18465150/pubmed\" id=\"18465150\" target=\"_blank\">",
"        18465150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaito H, Kamei K, Kikuchi E, et al, \"Successful Treatment of Collapsing Focal Segmental Glomerulosclerosis With a Combination of Rituximab, Steroids and Ciclosporin,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2010, 25(5):957-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/20033219/pubmed\" id=\"20033219\" target=\"_blank\">",
"        20033219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marks SD, Patey S, Brogan PA, et al, \"B Lymphocyte Depletion Therapy in Children With Refractory Systemic Lupus Erythematosus,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2005, 52(10):3168-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/16200620/pubmed\" id=\"16200620\" target=\"_blank\">",
"        16200620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milpied N, Vasseur B, Parquet N, et al, \"Humanized Anti-CD20 Monoclonal Antibody (Rituximab) in Post Transplant B-lymphoproliferative Disorder: A Retrospective Analysis on 32 Patients,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2000, 11 Suppl 1:113-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/10707791/pubmed\" id=\"10707791\" target=\"_blank\">",
"        10707791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parodi E, Rivetti E, Amendola G, et al, \"Long-Term Follow-Up Analysis After Rituximab Therapy in Children With Refractory Symptomatic ITP: Identification of Factors Predictive of a Sustained Response,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2009, 144(4):552-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/19036077/pubmed\" id=\"19036077\" target=\"_blank\">",
"        19036077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Provan D, Stasi R, Newland AC, et al, \"International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(2):168-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/19846889/pubmed\" id=\"19846889\" target=\"_blank\">",
"        19846889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prytua A, Iijima K, Kamei K, et al, \"Rituximab in Refractory Nephrotic Syndrome,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2010, 25(3):461-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/20033225/pubmed\" id=\"20033225\" target=\"_blank\">",
"        20033225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serinet MO, Jacquenin E, Habes D, et al, &ldquo;Anti-CD20 Monoclonal Antibody (Rituximab) Treatment for Epstein-Barr Virus-Associated, B-Cell Lymphoproliferative Disease in Pediatric Liver Transplant Recipients,&rdquo;",
"      <i>",
"       J Ped Gastroenterology &amp; Nutrition",
"      </i>",
"      , 2002, 34(4):389-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/11930095/pubmed\" id=\"11930095\" target=\"_blank\">",
"        11930095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang J, Wiley JM, Luddy R, et al, \"Chronic Immune Thrombocytopenic Purpura in Children: Assessment of Rituximab Treatment,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2005, 146(2):217-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/15689912/pubmed\" id=\"15689912\" target=\"_blank\">",
"        15689912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zecca M, Nobili B, Ramenghi U, et al, &ldquo;Rituximab for the Treatment of Refractory Autoimmune Hemolytic Anemia in Children,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 101(10):3857-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/47/34551/abstract-text/12531800/pubmed\" id=\"12531800\" target=\"_blank\">",
"        12531800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12971 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34551=[""].join("\n");
var outline_f33_47_34551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709404\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218842\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218843\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049762\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049754\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218822\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218808\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7882123\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049766\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11514605\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049757\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218877\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218875\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049770\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049753\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049752\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300009\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2197621\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218818\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218831\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049761\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049751\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049768\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049769\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049759\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12971|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=related_link\">",
"      Rituximab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/3/15414?source=related_link\">",
"      Rituximab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_47_34552="Schizophrenia: Clinical manifestations, course, assessment, and diagnosis";
var content_f33_47_34552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34552/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34552/contributors\">",
"     Bernard A Fischer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34552/contributors\">",
"     Robert W Buchanan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34552/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34552/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34552/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/47/34552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17284532\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizophrenia is a psychiatric disorder involving chronic or recurrent psychosis. It is commonly associated with impairments in social and occupational functioning. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/1\">",
"     1",
"    </a>",
"    ]. It is among the most disabling and economically catastrophic medical disorders, ranked by the World Health Organization as one of the top ten illnesses contributing to the global burden of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics of schizophrenia typically include positive symptoms such as hallucinations or delusions, disorganized speech, negative symptoms such as a flat affect or poverty of speech, and impairments in cognition including attention, memory and executive functions. A diagnosis of schizophrenia is based on the presence of such symptoms, coupled with social or occupational dysfunction for at least six months, in the absence of another diagnosis that would better account for the presentation.",
"   </p>",
"   <p>",
"    This topic discusses clinical manifestations, assessment, diagnosis, and course of schizophrenia. The epidemiology and pathogenesis of schizophrenia are discussed separately. Anxiety, depression, and substance abuse in schizophrenia are discussed separately. The treatments for schizophrenia are discussed separately, as are other psychotic disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20057?source=see_link\">",
"     \"Schizophrenia: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25944?source=see_link\">",
"     \"Depression in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2105?source=see_link\">",
"     \"Anxiety in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8904?source=see_link\">",
"     \"Psychosocial interventions for schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/15/1270?source=see_link\">",
"     \"Psychosocial interventions for severe mental illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284539\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with schizophrenia generally present with several areas of distinct psychopathology, as defined by DSM-IV-TR diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive symptoms",
"     </li>",
"     <li>",
"      Negative symptoms",
"     </li>",
"     <li>",
"      Cognitive impairment",
"     </li>",
"     <li>",
"      Mood symptoms",
"     </li>",
"     <li>",
"      Anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284546\">",
"    <span class=\"h2\">",
"     Positive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive symptoms represent an exaggeration of normal processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. This group of symptoms includes the reality distortion symptoms of hallucinations and delusions as well as disorganized thoughts and behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29948555\">",
"    <span class=\"h3\">",
"     Hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hallucinations are defined as the perception of a sensory process in the absence of an external source. They can be auditory, visual, somatic, olfactory, or gustatory.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Auditory hallucinations are the most common form of hallucination, with prevalence estimates between 40 and 80 percent in people with schizophrenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Although auditory hallucinations are frequently voices, they can take the form of other sounds such as music, body noises, or machinery. Some people with schizophrenia describe the sounds as coming from inside their head, whereas others can point to a specific external location from which they emanate. Auditory hallucinations are often the manifestation of the illness most responsive to antipsychotic medication. Many people with schizophrenia report antipsychotics &ldquo;turn down the volume&rdquo; of these hallucinations such that they can cope with them better.",
"     </li>",
"     <li>",
"      Visual hallucinations are often unformed, such as glowing orbs or flashes of color. However, some people with schizophrenia describe fully formed human figures, faces, or body parts.",
"     </li>",
"     <li>",
"      Somatic hallucinations can include feelings of being touched, of sexual intercourse, or of pain.",
"     </li>",
"     <li>",
"      Olfactory and gustatory hallucinations have not been systematically studied, but occasional patients will report a strange taste or smell.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29948685\">",
"    <span class=\"h3\">",
"     Delusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delusions, defined as a fixed, false belief, are present in approximately 80 percent of people with schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/8\">",
"     8",
"    </a>",
"    ]. Because insight into their illness may be impaired, people with schizophrenia often have delusional explanations for their hallucinations. Delusions are broadly categorized as bizarre or non-bizarre.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bizarre delusions are clearly implausible; they have no possibility of being true. Their content is not understandable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/3\">",
"       3",
"      </a>",
"      ]. Basic concepts may be described in an unusual way, eg, how the person experiences time, space, the self, or causality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/9\">",
"       9",
"      </a>",
"      ]. An example of a bizarre delusion is a patient&rsquo;s belief that aliens have cloned a patient a perfect body, but he must find a way to take off his head so that his spirit can flow into the new body.",
"     </li>",
"     <li>",
"      A non-bizarre delusion is one that while not true is understandable and has the possibility of being true. An example is that the IRS is after the patient for not paying taxes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The content of delusions can often be categorized as grandiose, paranoid, nihilistic, and erotomanic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grandiose delusions form around the belief that the person has some special significance or power.",
"     </li>",
"     <li>",
"      Paranoid delusions are clinically important because they may prevent the individual from cooperating with evaluation or treatment, and because they may increase the likelihood of problems like homelessness as the person goes &ldquo;off the grid&rdquo;.",
"     </li>",
"     <li>",
"      Nihilistic delusions are uncommon, bizarre beliefs that one is dead or one&rsquo;s body is breaking down or that one does not exist.",
"     </li>",
"     <li>",
"      In erotomanic delusions, the person erroneously believes that",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      has a special relationship with someone. These delusions can lead to legal problems such as restraining orders and trespass charges.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284560\">",
"    <span class=\"h3\">",
"     Disorganization",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with schizophrenia typically display some disorganization in behavior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thinking. Disorganized behaviors are directly observed while disorganized thoughts must be inferred from the patient&rsquo;s speech. Disjointed, disconnected speech patterns reflect a disruption in the organization of person&rsquo;s thoughts. The most commonly observed forms of abnormal speech are tangentiality and circumstantiality, while more severe thought disorder includes derailment, neologisms, and word salad. The symptoms of disorganization are independent of the severity of hallucinations or delusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tangential speech &mdash; The person gets increasingly further off the topic without appropriately answering a question.",
"     </li>",
"     <li>",
"      Circumstantial speech &mdash; The person will eventually answer a question, but in a markedly roundabout manner.",
"     </li>",
"     <li>",
"      Derailment &mdash; The person suddenly switches topic without any logic or segue.",
"     </li>",
"     <li>",
"      Neologisms &mdash; The creation of new, idiosyncratic words.",
"     </li>",
"     <li>",
"      Word salad &mdash; Words are thrown together without any sensible meaning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284567\">",
"    <span class=\"h2\">",
"     Negative symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;While positive symptoms represent an exaggeration of a normal process, negative symptoms are conceptualized as an absence or diminution of normal processes. Negative symptoms may be primary or secondary.",
"   </p>",
"   <p>",
"    Primary, enduring negative symptoms represent a core feature of schizophrenia; they are also referred to as deficit symptoms. Examples of negative symptoms include decreased expressiveness, apathy, flat affect, and a lack of energy. A table lists negative symptoms (",
"    <a class=\"graphic graphic_table graphicRef81542 \" href=\"mobipreview.htm?36/39/37499\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Primary negative symptoms are very resistant to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] and closely related to functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The severity of negative symptoms is independent of the reality distortion positive symptoms (ie, hallucinations and delusions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/16\">",
"     16",
"    </a>",
"    ]. A person may simultaneously have deficit symptoms and be quite psychotic, or have deficit symptoms in the absence of positive symptoms.",
"   </p>",
"   <p>",
"    Alternatively, negative symptoms may be secondary to other manifestations of the illness or its treatment. As examples, paranoia may lead to social isolation, and depression may lead to anergy. An unchanging facial expression may be an extrapyramidal side effect of medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2265295\">",
"    <span class=\"h3\">",
"     Deficit schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not a recognized DSM-IV-TR subtype of schizophrenia, people with schizophrenia who have prominent negative (or deficit) symptoms appear to represent a distinct subgroup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/16\">",
"     16",
"    </a>",
"    ]. People with deficit schizophrenia are less likely to have delusions with high emotional content (such as jealous delusions) compared to nondeficit schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. People categorized as deficit are least likely to show improvement and recovery over the course of the illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20057?source=see_link&amp;anchor=H296339#H296339\">",
"     \"Schizophrenia: Epidemiology and pathogenesis\", section on 'Deficit schizophrenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284574\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Areas of cognition that seem to be the most affected in schizophrenia are described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/19\">",
"     19",
"    </a>",
"    ]. It is not known whether these areas reflect multiple unique deficits, or a generalized deficit that affects multiple areas of cognition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Processing speed",
"     </li>",
"     <li>",
"      Attention",
"     </li>",
"     <li>",
"      Working memory",
"     </li>",
"     <li>",
"      Verbal learning and memory",
"     </li>",
"     <li>",
"      Visual learning and memory",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Reasoning/executive",
"      </span>",
"      functioning",
"     </li>",
"     <li>",
"      Verbal comprehension",
"     </li>",
"     <li>",
"      Social cognition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These impairments are reflected in the performance on neuropsychological tests among people with schizophrenia. On average, the neuropsychological test performance of someone with schizophrenia is one to two standard deviations lower than the performance of healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. If an individual tests within the normal range on any given neuropsychological battery, then his or her pre-morbid performance was very likely to have been above average. People with schizophrenia who appeared to lack cognitive impairment, when matched to healthy controls on age, education, and intelligence quotient (IQ), may actually show a unique pattern of performance deficits in memory and processing speed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Cognitive impairments probably precede the onset of positive symptoms. They are observed in people with first-episode schizophrenia, with a similar magnitude of performance impairment as seen in people with multi-episode schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/25\">",
"     25",
"    </a>",
"    ]. They are also observed in the family members of people with schizophrenia, though the magnitude of impairment is less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/26\">",
"     26",
"    </a>",
"    ]. In a study of monozygotic twins discordant for the disorder, affected twins performed worse on tests of memory and vigilance than the unaffected siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although antipsychotic medication and anticholinergic medication can impair cognition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], reports of memory disturbances in schizophrenia predate the advent of medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/30\">",
"     30",
"    </a>",
"    ]. The same pattern of cognitive dysfunction in people with schizophrenia is seen in both treated groups and those who have never been exposed to antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284581\">",
"    <span class=\"h2\">",
"     Mood and anxiety symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mood and anxiety symptoms are common in schizophrenia; mood and anxiety disorders appear to occur at a higher rate than in the general population. The epidemiology, clinical manifestations, diagnosis, and treatment of mood and anxiety symptoms in schizophrenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25944?source=see_link\">",
"     \"Depression in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2105?source=see_link\">",
"     \"Anxiety in schizophrenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284595\">",
"    <span class=\"h2\">",
"     Associated physical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several physical manifestations associated with schizophrenia, including neurological disturbances, catatonia, and metabolic disturbances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284602\">",
"    <span class=\"h3\">",
"     Neurological disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurological &ldquo;soft signs&rdquo; involve subtle impairments of sensory integration, motor coordination, and sequencing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/32\">",
"     32",
"    </a>",
"    ]. Examples of neurological soft signs are right-left confusion, agraphesthesia (the inability to recognize letters or numbers traced on the skin, usually on the palm of the hand), and astereognosia (the inability to identify familiar objects by touch alone). These neurological soft signs are observed in schizophrenia, are relatively stable, and are largely unrelated to medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Research findings have linked certain symptom domains to neurological signs, ie, sensory integration problems have been correlated with deficit symptoms, disorganization, and cognitive impairment, while impaired sequencing of complex motor behaviors has been correlated with disorganization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most neurological disturbances readily observed in people with schizophrenia are likely medication-induced. Antipsychotic dopamine blockade can cause extrapyramidal symptoms (EPS), such as tremor and bradykinesia, acute dystonias, akathisia (a subjective sense of restlessness or actual restlessness), or tardive (meaning &lsquo;late&rsquo;) dyskinesia (which includes abnormal peri-oral and other movements). However, descriptions of movement disorders including signs of pseudoparkinsonism, choreiform movements, and myoclonic jerking are common in the descriptions of schizophrenia that predate the development of antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=see_link\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284609\">",
"    <span class=\"h3\">",
"     Catatonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catatonia can present in schizophrenia as either extreme negativism, eg, motiveless motor resistance to instruction or attempts to move the person or mutism, or catatonic excitement, eg, excessive, purposeless motor activity. Catatonia is reviewed in more detail separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284616\">",
"    <span class=\"h3\">",
"     Metabolic disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizophrenia is associated with diabetes, hyperlipidemia, and hypertension. Although many antipsychotics cause metabolic disturbances including weight gain and diabetes, people with schizophrenia often have other risk factors for these conditions, including a sedentary lifestyle and smoking. There is also evidence from the pre-antipsychotic era and insulin coma treatments that schizophrenia itself is associated with insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/36\">",
"     36",
"    </a>",
"    ]. The life expectancy of people with schizophrenia is reduced by more than a decade compared to the general population. This excess mortality is largely mediated by heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115334799\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although earlier descriptions of schizophrenia suggested that the course was quite poor, the course actually shows considerable heterogeneity. One of the first and most influential longitudinal studies of the course of schizophrenia described eight course types, which differ in several ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset &mdash; Abrupt versus insidious",
"     </li>",
"     <li>",
"      Symptom presentation &mdash; Continuous versus intermittent",
"     </li>",
"     <li>",
"      Outcome &mdash; Poor versus non-poor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most people with schizophrenia in the study had an acute onset, intermittent symptoms, and later had no or only mild symptoms. Only about 20 percent had the stereotypical insidious onset, continuous symptoms, and poor outcome. In a re-examination of these data, participants were re-diagnosed with more stringent DSM and ICD criteria, and the results among those retaining a schizophrenia diagnosis were largely unchanged from the original course observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other influential longitudinal studies of schizophrenia demonstrate that the course of schizophrenia is not uniform and that there are subsets of individuals with fairly good outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. A 15 to 25 year follow-up of 644 participants with schizophrenia who participated in World Health Organization studies (including the International Pilot Study of Schizophrenia and the Determinants of Outcome of Severe Mental Disorders study) found that about half had favorable outcomes (minimal or no symptoms, employment, Global Assessment of Functioning (GAF) scores greater than 60) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, earlier in the illness, functional recovery is rarer. In a medication algorithm study, only about 14 percent of 118 people with a first episode of schizophrenia or schizoaffective disorder met recovery criteria for 2 or more years during the first 5 years of the illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/44\">",
"     44",
"    </a>",
"    ]. Recovery in this study was defined as no more than mild psychotic symptoms, no more than moderate negative symptoms, adequate role function (student, employment, homemaker), attention to hygiene, and independence in daily chores. An exception to this heterogeneity seems to be people with deficit schizophrenia, who seem to have a more consistently poor prognosis compared to their nondeficit peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DSM-IV-TR has several course specifiers that can also be used after one year of diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continuous (symptoms)",
"     </li>",
"     <li>",
"      Episodic with inter-episode residual symptoms",
"     </li>",
"     <li>",
"      Episodic with no inter-episode residual symptoms",
"     </li>",
"     <li>",
"      Single episode in partial remission",
"     </li>",
"     <li>",
"      Single episode in full remission",
"     </li>",
"     <li>",
"      Unspecified pattern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Recovery and remission",
"    </strong>",
"    &mdash; Over the past decade, consumer advocacy has drawn attention to the concept of recovery from schizophrenia. The model of recovery that has emerged differs from a strictly clinical model of recovery (eg, no or mild symptoms, restored functioning). The consumer-driven model is a blend of function, life-satisfaction, and independence. Despite scientific efforts to capture this outcome, there are no currently accepted scales to measure recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The more clinically useful concept may be remission of schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/46\">",
"     46",
"    </a>",
"    ]. In remission, the individual has no or minimal symptoms that do not interfere with behavior for a period of six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/47\">",
"     47",
"    </a>",
"    ]. Remission, in turn, is necessary but insufficient for the process of recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284623\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of schizophrenia is often one of exclusion. No symptom or group of symptoms is pathognomonic for schizophrenia, however, there are specific hallucinations and delusions that are often considered characteristic of the illness, known as &ldquo;first-rank symptoms&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/48\">",
"     48",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef76914 \" href=\"mobipreview.htm?19/9/19611\">",
"     table 2",
"    </a>",
"    ). Although up to 25 percent of manic bipolar patients endorse first-rank symptoms in cross-sectional studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/8\">",
"     8",
"    </a>",
"    ], and about 45 percent in longitudinal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/49\">",
"     49",
"    </a>",
"    ], upwards of 85 percent of people with schizophrenia endorse them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. There are no laboratory or physical examination findings or other biomarkers that are useful in making the diagnosis. Rather, physical and laboratory assessments may be useful in ruling out other medical causes of psychosis (eg, the presence of Kayser-Fleischer rings may indicate Wilson&rsquo;s disease).",
"   </p>",
"   <p>",
"    The patient assessment is based on the diagnostic interview supplemented by collateral information. Family members or caregivers are often a good source of information about a patient&rsquo;s clinical presentation outside the office or hospital. Medical records, especially from the initial presentation of the illness and most recent hospitalization, can give additional information.",
"   </p>",
"   <p>",
"    Working with patients who are uncooperative, whether from paranoia or for other reasons, can be challenging. Even if a person denies hearing voices, it is sometimes observed that he or she seems to be responding to internal stimulation (by smiling inappropriately, looking in the direction from where they hear a voice, or seeming distracted during an interview). Although there are other reasons a person might act this way, and diagnosis should not be based solely on these observations, the behaviors of a person may provide useful information as to their ongoing internal experiences.",
"   </p>",
"   <p>",
"    Assessment of someone with schizophrenia should include evaluations of health including cholesterol, blood glucose, weight and BMI, prolactin, evaluation of motor disturbances, and a urine drug screen.",
"   </p>",
"   <p>",
"    In the course of assessment and ongoing clinical care, the clinician can be a critical source of compassion and education for the patient and family. Along with treatment for their symptoms and medication side effects, the patient may need help coping with disabilities, associated losses, and the stigma associated with the diagnosis of schizophrenia. This stigma can be as damaging as the direct effects of the illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17284630\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis is central to the diagnosis of schizophrenia under the DSM-IV-TR classification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/51\">",
"     51",
"    </a>",
"    ]. See table for diagnostic criteria (",
"    <a class=\"graphic graphic_table graphicRef54426 \" href=\"mobipreview.htm?1/26/1453\">",
"     table 3",
"    </a>",
"    ). The diagnosis of schizophrenia requires the presence of &ldquo;characteristic symptoms&rdquo; of the disorder (referred to as the &ldquo;A-criteria&rdquo;) coupled with social",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occupational dysfunction for at least six months in the absence of another diagnosis that would better account for the presentation (such as drug use, certain medical conditions, or psychotic mood disorders).",
"   </p>",
"   <p>",
"    Characteristic symptoms of schizophrenia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delusions",
"     </li>",
"     <li>",
"      Hallucinations",
"     </li>",
"     <li>",
"      Disorganized speech",
"     </li>",
"     <li>",
"      Disorganized or catatonic behavior",
"     </li>",
"     <li>",
"      Negative symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Under the diagnostic criteria, at least two of these five A-criteria symptoms must be present, unless delusions are bizarre or if the hallucination is voices",
"    <span class=\"nowrap\">",
"     arguing/discussing",
"    </span>",
"    or a voice commenting, in which case only one of the five symptoms is needed. If there are prominent negative symptoms, this can be noted as a specifier to the diagnosis (ie, &ldquo;With Prominent Negative Symptoms&rdquo;). There are five subtypes of schizophrenia, which are summarized in a figure (",
"    <a class=\"graphic graphic_algorithm graphicRef56991 \" href=\"mobipreview.htm?2/10/2209\">",
"     algorithm 1",
"    </a>",
"    ). However, there is little evidence that these subtypes are particularly stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/52\">",
"     52",
"    </a>",
"    ], that they cluster in families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34552/abstract/53\">",
"     53",
"    </a>",
"    ], or that they provide any clinical utility beyond describing someone&rsquo;s presentation at the time the diagnosis was made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H422401\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common psychiatric disorders in the differential diagnosis of schizophrenia include schizophreniform disorder, schizoaffective disorder, bipolar disorder, and major depression with psychotic features, and substance-induced psychotic disorders",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In schizophreniform disorder all the criteria for schizophrenia are met, but the total duration of the disorder is less than six months.",
"     </li>",
"     <li>",
"      Schizoaffective, bipolar disorder, and major depression with psychotic features all differ from schizophrenia in that there is a prominent mood component to the person&rsquo;s presentation.",
"     </li>",
"     <li>",
"      Schizoaffective disorder is essentially schizophrenia with manic episodes or a significant depressive component",
"     </li>",
"     <li>",
"      The difference between mood disorders with psychosis and schizoaffective disorder is the timing of symptoms. In schizoaffective disorder, psychosis can and does occur in the absence of a mood episode; in psychotic mood disorders the psychosis is only observed in the presence of a mood episode.",
"     </li>",
"     <li>",
"      In substance-induced psychotic disorders the symptoms are a manifestation of intoxication or acute withdrawal and do not persist after the individual is sober.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Often, the only way to definitively differentiate among these diagnoses is with longitudinal follow-up. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/37/44625?source=see_link\">",
"       \"Patient information: Schizophrenia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6053776\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. Michael D. Jibson for his contributions to earlier versions of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6053783\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations of schizophrenia include positive and negative symptoms, cognitive impairment, and mood or anxiety symptoms. Positive symptoms include hallucinations, delusions, and disorganization. (See",
"      <a class=\"local\" href=\"#H17284546\">",
"       'Positive symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hallucinations are defined as the perception of a sensory process in the absence of an external source. They can be auditory, visual, somatic, olfactory, or gustatory.",
"     </li>",
"     <li>",
"      Delusions are defined as a fixed, false belief. They can be bizarre or non-bizarre. Their content can often be categorized as grandiose, paranoid, nihilistic, or erotomanic.",
"     </li>",
"     <li>",
"      Disorganization can typically be seen in both behavior and speech. The most commonly observed forms of abnormal speech are tangentiality and circumstantiality, while more severe thought disorder includes derailment, neologisms, and word salad.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary, enduring negative symptoms represent a core feature of schizophrenia; they are also referred to as deficit symptoms. Examples of negative symptoms include a flat affect, poverty of speech, and a lack of interest or energy. A table lists other negative symptoms (",
"      <a class=\"graphic graphic_table graphicRef81542 \" href=\"mobipreview.htm?36/39/37499\">",
"       table 1",
"      </a>",
"      ). Secondary negative symptoms can be caused by antipsychotic medications. (See",
"      <a class=\"local\" href=\"#H17284567\">",
"       'Negative symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical manifestations of schizophrenia include neurological &ldquo;soft signs&rdquo;, catatonia, and metabolic disturbances. Metabolic abnormalities and movement disorders can be caused by schizophrenia itself as well as by antipsychotic medications. (See",
"      <a class=\"local\" href=\"#H17284595\">",
"       'Associated physical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of schizophrenia (",
"      <a class=\"graphic graphic_table graphicRef54426 \" href=\"mobipreview.htm?1/26/1453\">",
"       table 3",
"      </a>",
"      ) requires the presence of two of the five characteristic symptoms below (the DSM-IV-TR A-criteria) coupled with social",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occupational dysfunction for at least six months, and the absence of another diagnosis that would better account for the presentation (such as drug use, certain medical conditions, or psychotic mood disorders). (See",
"      <a class=\"local\" href=\"#H17284630\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Delusions",
"     </li>",
"     <li>",
"      Hallucinations",
"     </li>",
"     <li>",
"      Disorganized speech",
"     </li>",
"     <li>",
"      Disorganized or catatonic behavior",
"     </li>",
"     <li>",
"      Negative symptoms",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     Murray CJL, Lopez AD. The Global Burden of Disease, Harvard University Press, Cambridge, MA 1996. p.21.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/4\">",
"      Carpenter WT Jr, Strauss JS, Bartko JJ. The diagnosis and understanding of schizophrenia. Part I. Use of signs and symptoms for the identification of schizophrenic patients. Schizophr Bull 1974; :37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/5\">",
"      Bartko JJ, Strauss JS, Carpenter WT Jr. The diagnosis and understanding of schizophrenia. Part II. Expanded perspectives for describing and comparing schizophrenic patients. Schizophr Bull 1974; :50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/6\">",
"      Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974; :61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/7\">",
"      Thomas P, Mathur P, Gottesman II, et al. Correlates of hallucinations in schizophrenia: A cross-cultural evaluation. Schizophr Res 2007; 92:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/8\">",
"      Andreasen NC, Flaum M. Schizophrenia: the characteristic symptoms. Schizophr Bull 1991; 17:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/9\">",
"      Cermolacce M, Sass L, Parnas J. What is bizarre in bizarre delusions? A critical review. Schizophr Bull 2010; 36:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/10\">",
"      Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982; 39:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/11\">",
"      Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/12\">",
"      Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/13\">",
"      Kirkpatrick B, Kopelowicz A, Buchanan RW, Carpenter WT Jr. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 2000; 22:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/14\">",
"      Strauss GP, Harrow M, Grossman LS, Rosen C. Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophr Bull 2010; 36:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/15\">",
"      Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994; 151:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/16\">",
"      Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001; 58:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/17\">",
"      Kirkpatrick B, Amador XF, Flaum M, et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res 1996; 20:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/18\">",
"      Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis 1994; 182:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/19\">",
"      Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 72:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/20\">",
"      Gold JM, Hahn B, Strauss GP, Waltz JA. Turning it upside down: areas of preserved cognitive function in schizophrenia. Neuropsychol Rev 2009; 19:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/21\">",
"      Dickinson D, Iannone VN, Wilk CM, Gold JM. General and specific cognitive deficits in schizophrenia. Biol Psychiatry 2004; 55:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/22\">",
"      Kraus MS, Keefe RS. Cognition as an outcome measure in schizophrenia. Br J Psychiatry Suppl 2007; 50:s46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/23\">",
"      Wilk CM, Gold JM, McMahon RP, et al. No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology 2005; 19:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/24\">",
"      Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997; 11:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/25\">",
"      Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/26\">",
"      Snitz BE, Macdonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006; 32:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/27\">",
"      Goldberg TE, Ragland JD, Torrey EF, et al. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 1990; 47:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/28\">",
"      Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006; 85:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/29\">",
"      Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     Kraepelin E. Dementia Praecox and Paraphrenia, Krieger, New York 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/31\">",
"      Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res 2002; 58:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/32\">",
"      Heinrichs DW, Buchanan RW. Significance and meaning of neurological signs in schizophrenia. Am J Psychiatry 1988; 145:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/33\">",
"      Bombin I, Arango C, Buchanan RW. Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull 2005; 31:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/34\">",
"      Arango C, Kirkpatrick B, Buchanan RW. Neurological signs and the heterogeneity of schizophrenia. Am J Psychiatry 2000; 157:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/35\">",
"      Arango C, Bartko JJ, Gold JM, Buchanan RW. Prediction of neuropsychological performance by neurological signs in schizophrenia. Am J Psychiatry 1999; 156:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/36\">",
"      Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004; 47:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/37\">",
"      Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115.",
"     </a>",
"    </li>",
"    <li>",
"     Blueler M. The Schizophrenic Disorders: Long-Term Patient and Family Studies, Yale University Press, London 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/39\">",
"      Modestin J, Huber A, Satirli E, et al. Long-term course of schizophrenic illness: Bleuler's study reconsidered. Am J Psychiatry 2003; 160:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/40\">",
"      Harding CM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. Am J Psychiatry 1987; 144:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/41\">",
"      Harding CM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 1987; 144:727.",
"     </a>",
"    </li>",
"    <li>",
"     Recovery from Schizophrenia: An International Perspective; A Report from the WHO Collaborative Project, The International Study of Schizophrenia, Hopper K, Harrison G, Janca A, Sartorius N.  (Eds), Oxford University Press, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/43\">",
"      Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001; 178:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/44\">",
"      Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/45\">",
"      Bellack AS. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull 2006; 32:432.",
"     </a>",
"    </li>",
"    <li>",
"     Fischer BA, Carpenter WT. Remission. In: Clinical Handbook of Schizophrenia, Mueser KT, Jeste DV.  (Eds), Guilford Publications, New York 2008. p.559.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/47\">",
"      Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162:441.",
"     </a>",
"    </li>",
"    <li>",
"     Schneider K. Clinical Psychopathology, Grune &amp; Stratton, New York 1959.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/49\">",
"      Rosen C, Grossman LS, Harrow M, et al. Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder. Compr Psychiatry 2011; 52:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/50\">",
"      Thorup A, Petersen L, Jeppesen P, Nordentoft M. Frequency and predictive values of first rank symptoms at baseline among 362 young adult patients with first-episode schizophrenia Results from the Danish OPUS study. Schizophr Res 2007; 97:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/51\">",
"      Fischer BA, Carpenter WT Jr. Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology 2009; 34:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/52\">",
"      Kendler KS, Gruenberg AM, Tsuang MT. Subtype stability in schizophrenia. Am J Psychiatry 1985; 142:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34552/abstract/53\">",
"      Kendler KS, Gruenberg AM, Tsuang MT. A family study of the subtypes of schizophrenia. Am J Psychiatry 1988; 145:57.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6962 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-BD5B12EED9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34552=[""].join("\n");
var outline_f33_47_34552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6053783\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17284532\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17284539\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17284546\">",
"      Positive symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29948555\">",
"      - Hallucinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29948685\">",
"      - Delusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17284560\">",
"      - Disorganization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17284567\">",
"      Negative symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2265295\">",
"      - Deficit schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17284574\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17284581\">",
"      Mood and anxiety symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17284595\">",
"      Associated physical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17284602\">",
"      - Neurological disturbances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17284609\">",
"      - Catatonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17284616\">",
"      - Metabolic disturbances",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115334799\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17284623\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17284630\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H422401\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6053776\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6053783\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/6962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/6962|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?2/10/2209\" title=\"algorithm 1\">",
"      Decision tree for diagnosing schizophrenia subtype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/6962|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/39/37499\" title=\"table 1\">",
"      Negative symptoms in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/9/19611\" title=\"table 2\">",
"      First-rank symptoms in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/26/1453\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for schizophrenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2105?source=related_link\">",
"      Anxiety in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=related_link\">",
"      Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25944?source=related_link\">",
"      Depression in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/37/44625?source=related_link\">",
"      Patient information: Schizophrenia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8904?source=related_link\">",
"      Psychosocial interventions for schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/15/1270?source=related_link\">",
"      Psychosocial interventions for severe mental illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20057?source=related_link\">",
"      Schizophrenia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_47_34553="Prenatal assessment of gestational age";
var content_f33_47_34553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal assessment of gestational age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Andrew P MacKenzie, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Courtney D Stephenson, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Edmund F Funai, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/47/34553/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/47/34553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography has advanced obstetric practice by enabling relatively detailed assessment of the fetus in utero, including an accurate estimate of gestational age when performed in the first half of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/1\">",
"     1",
"    </a>",
"    ]. This information is invaluable because most obstetrical management decisions are strongly influenced by consideration of fetal development, which closely correlates with fetal age.",
"   </p>",
"   <p>",
"    Fetal biometric measurements used to calculate gestational age will be reviewed here. The discussion of dating will be based on time since the last menstrual period (menstrual age), not time since conception (conceptional or embryonic age).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two clinical methods of gestational age assessment are history, using the date of the last menstrual period (LMP) to calculate the estimated date of delivery (\"due date\" or EDD), and physical examination. The clinical assessment of gestational age or duration of pregnancy reflects the \"menstrual age.\" In contrast, embryologists always date developmental events from the time of fertilization, which is the \"embryonic age.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Naegele's rule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Naegele's rule is the most common method of pregnancy dating. The EDD is calculated by counting back three months from the last menstrual period and adding seven days. As an example, if the last menstrual period is February 20, then the EDD will be November 27. If the last menstrual period is May 28, the EDD will be March 4. This method assumes the patient has a 28-day menstrual cycle with fertilization occurring on day 14. Inaccuracy occurs because many women do not have regular 28-day cycles or conceive on day 14, and many others are not certain of the date of their last period. In addition, early pregnancy bleeding or recent use of hormonal contraceptives may lead to an incorrect assumption of the date of ovulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Calculator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculators that determine EDD and current gestational age are widely available (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?41/5/42067?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?8/55/9074?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Uterine size",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, the pregnant uterus is soft and globular. The size - gestational age correlation is learned by experience and is often described in terms of fruit (eg, 6 to 8 week size = small pear, 8 to 10 week size = orange, 10 to 12 week size = grapefruit). The uterus remains a pelvic organ until approximately 12 weeks of gestation, when it becomes sufficiently large to palpate abdominally just above the symphysis pubis. At 16 weeks, the uterine fundus is palpable midway between the symphysis pubis and umbilicus, and at 20 weeks it is palpable at the level of the umbilicus. Leiomyoma, obesity, and other factors affecting uterine size or the ability to palpate the uterus (eg, retroverted position), interfere with accurate assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SONOGRAPHIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is commonly used to estimate gestational age and thereby calculate the expected date of delivery (EDD). Several studies have demonstrated that ultrasound estimation of EDD in the first half of pregnancy is superior to dating based on the last menstrual period or physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These findings are illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 34,249 singleton pregnancies with both certain menstrual dates and ultrasonographic biometry reported that delivery occurred within seven days of the EDD more often when sonography alone, rather than last menstrual period alone, was used to calculate the delivery date (55.2 versus 49.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/1\">",
"       1",
"      </a>",
"      ]. Certain menstrual dates was defined as patient certain of her last menstrual period, with regular menstrual cycles, and no use of oral contraceptives in the preceding three months. Sonography was performed transabdominally, 95 percent of patients were scanned between 13 and 24 weeks.",
"     </li>",
"     <li>",
"      A systematic review found reduced rates of induction of labor for postterm pregnancy (OR 0.68, 95% CI 0.57-0.82) among women who underwent ultrasound examination in early pregnancy (before 24 weeks) and concluded that routine ultrasound in early pregnancy enabled better gestational age assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a study of 44,623 women who had both a normal last menstrual period and ultrasound examination before 20 weeks of gestation found that sonographic dating resulted in a small downward estimation of gestational age more often than an upward estimation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/3\">",
"     3",
"    </a>",
"    ]. This finding is consistent with other series showing that delayed ovulation (after day 14) occurs more often than early ovulation. Because routine ultrasound examination has the net effect of reducing the estimated gestational age, populations assigned an EDD by routine sonographic examination have a lower rate of induction for postterm birth than those assigned an EDD by menstrual dating (2 versus 3 percent); on the other hand, they have a higher rate of preterm delivery (9.1 versus 7.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First trimester sonographic gestational age assessment is more effective for decreasing the rate of postterm induction than second trimester assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/4\">",
"     4",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic estimation is particularly important when menstrual cycles are irregular, the last menstrual period is unknown, and in patients who conceive while using hormonal contraception. Ultrasound is also used to establish a pregnancy's duration when the uterine size estimated on physical examination differs from that predicted by menstrual dating. Some causes for a discrepancy between the perceived uterine size and that expected by last menstrual period include uterine leiomyomata, uterine malposition (eg, retroverted uterus), and multiple gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since gestational age calculations are based upon biometric measurements, the optimal time to obtain an estimate of gestational age is during the first trimester when biologic variation in size from fetus to fetus is minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5\">",
"     5",
"    </a>",
"    ]. First trimester sonograms can be performed via the transvaginal (TVS)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the transabdominal (TAS) route. The preferred mode depends on both the gestational age at the time of the study and the patient's pelvic and abdominal anatomy. In the earliest stages of pregnancy, TVS generally provides clear and accurate images while TAS may be unable to even detect an intrauterine gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/6\">",
"     6",
"    </a>",
"    ]. Therefore, TVS is typically used for early first trimester evaluation of the gestational sac, yolk sac, and developing embryo. Measurement of crown rump length in early gestation is easier with TVS than TAS, but not more accurate for determining gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/7\">",
"     7",
"    </a>",
"    ]. As the uterus grows out of the pelvis into the mid and upper abdomen and the fetus gets larger, TAS usually provides better visualization of the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gestational sac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using transvaginal sonography: the gestational sac is usually visible at 4.5 to 5 weeks of gestation, with a double decidual sign appearing at 5.5 to 6 weeks.",
"   </p>",
"   <p>",
"    During the first three to five weeks of pregnancy (conceptus phase), the endometrium has a \"trilaminar\" appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]; sonographic evaluation does not show distinct evidence of an intrauterine pregnancy at this time. The gestational sac is the first sonographic sign of an intrauterine pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5\">",
"     5",
"    </a>",
"    ], and appears as a small, fluid filled, sac-like structure eccentrically located within the endometrium. This structure and its echogenic rim represent the chorionic cavity, implanting chorionic villi, and associated decidual tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/10\">",
"     10",
"    </a>",
"    ]. This \"intradecidual sign\" is not consistently sensitive or specific for gestational age assessment, thus it is not used for calculating an EDD.",
"   </p>",
"   <p>",
"    If there are no distinct structures within the gestational sac, then initial dating measurements are based on sac diameter. To correctly measure sac diameter, the cursors should be placed on the sac itself and should not include the echogenic region surrounding the gestational sac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5\">",
"     5",
"    </a>",
"    ]. A size of 2 to 3 mm is the smallest size that can be clearly visualized within the uterine cavity and correlates with a gestational age of approximately four weeks and one to three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. As the gestation progresses, the sac (chorionic cavity) enlarges; the appearance and thickness of the decidua basalis changes over time, until it can no longer be identified at 10 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/14\">",
"     14",
"    </a>",
"    ]; the decidua capsularis becomes stretched and ultimately merges with the decidua parietalis.",
"   </p>",
"   <p>",
"    Gestational age based upon gestational sac measurements can be calculated in several ways. One standardized formula that is frequently used is the Mean Sac Diameter (MSD), which is derived by calculating the mean of the three orthogonal sac diameter measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. The gestational age can then be determined by consulting a table showing gestational age according to MSD. A simplified method of estimating gestational age is to calculate the sum of 30 plus the sac size in millimeters; this number is equivalent to the gestational age in days. As an example, using a sac size of 5 mm, the calculated age would be 35 days (30+5) or five weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5,12,15,19\">",
"     5,12,15,19",
"    </a>",
"    ]. The early gestational sac grows by approximately 1 mm per day, or 7 mm per week. Gestational sac measurement is less accurate later in pregnancy, when the embryonic or fetal pole can be identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]; therefore, it is used for dating only very early pregnancies.",
"   </p>",
"   <p>",
"    The shape of the sac may change from a circular to an irregular appearance on subsequent examinations. This may be indicative of various physiologic and anatomic factors (ie, uterine contractions, enlarged bladder, fibroids, implantation bleeds) or may be an ominous sign of a failed pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link&amp;anchor=H31#H31\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Diagnostic evaluation of threatened abortion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The crown rump length is a more accurate indicator of gestational age than mean gestational sac diameter so once the embryonic pole is evident and crown rump length should be used to determine an EDD. However, this mean sac diameter may be recorded when an embryo is not identified. Caution should be used in making the presumptive diagnosis of a gestational sac in the absence of a definite embryo or yolk sac. Without these findings, an intrauterine fluid collection could represent a pseudogestational sac associated with an ectopic pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Yolk sac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The yolk sac is the first anatomic structure to appear within the gestational sac and provides confirmation of an intrauterine pregnancy. The yolk sac is spherical with a sonolucent center and echogenic periphery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65928 \" href=\"mobipreview.htm?38/41/39572\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5\">",
"     5",
"    </a>",
"    ]. It can be noted initially at the beginning of the 5th week of gestation (MSD approximately 5 mm), although it may not appear until the MSD approaches 8 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Therefore, reasonable criteria for an abnormal gestation are MSD of 8 mm or greater with an absent yolk sac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/21\">",
"     21",
"    </a>",
"    ]. However, since there is patient and scanning variability, this sac size should not be taken as an absolute threshold for diagnosis of an abnormal pregnancy. Either correlation with hCG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sonographic follow-up should be obtained if an initial evaluation of pregnancy shows an 8 mm empty sac without a yolk sac.",
"   </p>",
"   <p>",
"    The yolk sac continues to grow to a maximum diameter of approximately 6 mm by 10 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. During this natural progression, the yolk sac migrates to the periphery of the chorionic cavity, and becomes undetectable sonographically by the end of the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By identifying the yolk sac, the embryonic disc (ie, the thickened region along the outer-most margin of the yolk sac) is also located [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/15,21,27,28\">",
"     15,21,27,28",
"    </a>",
"    ]. The embryonic disc becomes visible at 1 to 2 mm in length, which correlates with a gestational age of five to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, the gestational sac and yolk sac lose their accuracy for gestational age assessment as the pregnancy advances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. Direct measurement of the crown rump length of the embryo provides the most accurate estimate of gestational age once the embryonic pole is evident and should be used to determine an EDD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Crown rump length",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crown-rump length (CRL) is the standard biometric measurement of the embryo in the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. By definition, the crown-rump length is the longest straight-line measurement of the embryo measured from the outer margin of the cephalic pole to the rump [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A length of at least 5 mm routinely allows visualization of the embryo (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71198 \" href=\"mobipreview.htm?11/5/11351\">",
"     image 2",
"    </a>",
"    ), but some embryos as small as 2 to 3 mm can be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. Tables have been formulated to estimate gestational age for each numeric measurement of CRL up to 120 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/33,35-37\">",
"     33,35-37",
"    </a>",
"    ]. In general, when the CRL is under 25 mm, the GA (in days) is CRL + 42 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard practice for determining gestational age is to take the mean of three CRL measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5\">",
"     5",
"    </a>",
"    ]. When CRL is measured between 7 and 10 weeks, this method is accurate within three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/29,33,35,38\">",
"     29,33,35,38",
"    </a>",
"    ]. However, accuracy wanes as the gestation progresses. Estimation of gestational age by CRL between 10 and 14 weeks is accurate within &plusmn; 5 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/36,39,40\">",
"     36,39,40",
"    </a>",
"    ], and expands to within &plusmn; 8.4 days at 15 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/36\">",
"     36",
"    </a>",
"    ]. This variation has been attributed to normal biological differences in embryologic development and variations in anatomical positioning of the fetal head and torso [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Both first trimester growth delay and growth acceleration are active areas of investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5783?source=see_link\">",
"     \"Diagnosis and outcome of first trimester growth delay\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these variations, some experts prefer that estimation of gestational age by CRL measurement be limited to gestations of 6 to 10 weeks, and suggest alternative biometric studies (biparietal diameter, head circumference) for gestational age assessment later in the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5\">",
"     5",
"    </a>",
"    ]. The goal of these additional measurements is to improve fetal dating after the 10th week of gestation when test performance of CRL measurement diminishes. However, these measurements have not been proven to perform better than CRL in the late first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/44-47\">",
"     44-47",
"    </a>",
"    ], and are more technically challenging this early in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/5\">",
"     5",
"    </a>",
"    ]. For these reasons, the CRL remains the standard biometric measurement for first trimester estimation of gestational age up to 14 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cardiac activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the embryo is visible, but too small to measure adequately, detection of cardiac activity establishes a gestational age of 5.5 to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Second and third trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four standard biometric parameters commonly used to estimate gestational age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal weight in the second and third trimesters are: biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/44\">",
"     44",
"    </a>",
"    ]. They are typically obtained by transabdominal ultrasound examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/25?source=see_link\">",
"     \"Prenatal sonographic assessment of fetal weight\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Biparietal diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biparietal diameter (BPD) is the best studied biometric parameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/36,48-54\">",
"     36,48-54",
"    </a>",
"    ] because it is highly reproducible and can predict gestational age within &plusmn;7 days when measured between 14 and 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/41,42,48-50\">",
"     41,42,48-50",
"    </a>",
"    ]. Unfortunately, test performance diminishes as the gestation progresses beyond this period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/50,51,55\">",
"     50,51,55",
"    </a>",
"    ]. By the mid to late third trimester, the margin of error is three to four weeks. This significant variation is likely due to a large normal biological variation in fetal shape and size near term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/50,56,57\">",
"     50,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BPD is measured on a plane of section that intersects both the third ventricle and thalami (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56629 \" href=\"mobipreview.htm?17/61/18387\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20,58\">",
"     20,58",
"    </a>",
"    ]. This standardized method of measurement helps to ensure reproducibility among examiners. To further enhance test performance, the calvarium should appear smooth and symmetrical in the plane of section. The appropriate image can be obtained by positioning the abdominal transducer perpendicular to the fetal parietal bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. The cursors are then placed on the outer edge of the proximal skull and the inner edge of the distal skull; this length represents the BPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20,58,59\">",
"     20,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cephalic index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal cranium may not always display a traditional shape, particularly with breech presentations, oligohydramnios, premature rupture of the membranes, and neural tube abnormalities. Head compression or distortion from these conditions may result in an abnormal cranial conformation (eg, dolichocephaly) that lowers test performance of the BPD for gestational age estimation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20,60,61\">",
"     20,60,61",
"    </a>",
"    ]. In these cases, the cephalic index should be measured.",
"   </p>",
"   <p>",
"    Cephalic index (CI) refers to the ratio of the BPD and the occipitofrontal diameter (OFD) multiplied by 100 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. The standard CI range for normal shaped craniums approximates one standard deviation from the mean (&gt;74 or &lt;83) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/62\">",
"     62",
"    </a>",
"    ]. Therefore, if the CI measurement approaches the outer limits of the normal range, the use of the BPD for estimation of gestational age is not accurate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In these cases, head circumference (HC) (discussed below) is recommended for cranial assessment because it provides a good estimate of gestational age despite the fetus' irregular cranial structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Head circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the fetal head circumference (HC) provides a good estimate of gestational age on routine sonograms, but also is useful in the clinical setting of growth disorders when other measures may not perform well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/48,56,64-68\">",
"     48,56,64-68",
"    </a>",
"    ]. The accuracy is within one week prior to 20 weeks of gestational age; some studies have even demonstrated superiority when compared to the BPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/48,57,64-67\">",
"     48,57,64-67",
"    </a>",
"    ]. As with other biometric measures, test performance falls in the second half of pregnancy and, by the late third trimester, variability can be within three to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/48,49,54,56\">",
"     48,49,54,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The correct plane for the image passes through the thalami and third ventricle, and is similar to the plane for the BPD. However, additional intracerebral landmarks that must be visualized to obtain the appropriate measurement include the cavum septum pellucidum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51474 \" href=\"mobipreview.htm?29/62/30689\">",
"     image 4",
"    </a>",
"    ) anteriorly and the tentorial hiatus posteriorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. This view depicts the greatest anterior-posterior length of the cranium and resembles an \"arrow\" with the anterior portion appearing as tail feathers, the third ventricle and Sylvian aqueduct as the shaft, and the actual arrowhead comprised of the ambient and quadrigeminal cisterns and the tentorial hiatus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. The standard view should not include the cerebellum or the cerebral ventricles.",
"   </p>",
"   <p>",
"    The calvarium should always appear symmetrical in the image. HC measurements are obtained by placing the cursors on the outer margins of the calvarium bilaterally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ], in contrast to BPD measurements, which extend from the inner calvarium on one side to the outer calvarium on the other side. By using the computerized ellipse function, the ultrasound machine will assist in the approximation of the outer perimeter of the calvarium. It is important to avoid measuring the outer margin of the skin overlying the scalp, since doing so will falsely increase the HC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Femur length",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femur length (FL) can be measured as early as 10 weeks gestational age because of its size and echogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. Correlation with true gestational age is within one week prior to 20 weeks gestational age, but falls to within 2.1 to 3.5 weeks in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/57,65,67,69-72\">",
"     57,65,67,69-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though FL is a simple \"one-dimensional\" image, errors in measurement often occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. The transducer should be aligned along the long axis of the femoral bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]; the proper view is obtained by visualizing either the femoral head or the greater trochanter at the proximal end of the femur and the femoral condyle at the distal end [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/73\">",
"     73",
"    </a>",
"    ]. The calipers should be placed at the junction of bone and cartilage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50944 \" href=\"mobipreview.htm?32/16/33027\">",
"     image 5",
"    </a>",
"    ) to measure only ossified bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/73\">",
"     73",
"    </a>",
"    ]; they should not contain the femoral head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/40\">",
"     40",
"    </a>",
"    ]. Including nonossified portions of the femur and not visualizing the full femur (femoral",
"    <span class=\"nowrap\">",
"     head/greater",
"    </span>",
"    trochanter to femoral condyle) are the major sources of error in gestational age assessment by FL. The former overestimates and the latter underestimates gestational age.",
"   </p>",
"   <p>",
"    Average femur length appears to vary slightly among ethnic groups. Short femurs may be a normal finding or a marker of aneuploidy (trisomy 21). Severely shortened (&lt;5th percentile) or abnormal appearing femurs in the second trimester suggest a skeletal dysplasia or early onset fetal growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Abdominal circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal circumference (AC) appears to have a slightly lower ability to predict gestational age early in the second trimester than the BPD, HC, and FL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/57,65-67\">",
"     57,65-67",
"    </a>",
"    ]. Some of the variability may be due to error in ultrasound technique, along with natural biologic variations. In the second trimester, gestational age assessment is accurate within two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/78\">",
"     78",
"    </a>",
"    ]. In the late third trimester, variability increases so accuracy falls to within three to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/57,78\">",
"     57,78",
"    </a>",
"    ]. Due to the wide margin of error, AC is often used for estimations of fetal weight and interval growth evaluations rather than gestational age assessment. However, the AC can be a valuable additional measure for dating during the second trimester, especially in fetuses with cranial or limb abnormalities.",
"   </p>",
"   <p>",
"    Measuring the AC is challenging since the abdomen is neither as symmetrical nor as echogenic as the cranium and femur, and changes during fetal breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. Therefore, the AC is not as easily measured. The image is taken at the level of the largest diameter of the fetal liver, denoted by the point of union of the right and left portal veins, which has a \"hockey stick\" appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74022 \" href=\"mobipreview.htm?9/29/9681\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/79\">",
"     79",
"    </a>",
"    ]. This plane was chosen because the size of the liver correlates well with overall fetal growth. The correct plane can be confirmed by visualizing the umbilical segment of the left portal vein in its shortest length. If the cross-section through the fetal abdomen is skewed caudally, this vein will appear in a longer image [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. Two additional guidelines for correct measurement are (1) positioning the transducer perpendicularly to the fetal abdominal wall and (2) visualizing the symmetrical appearance of the lower ribs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. The fetal stomach is typically visualized on the AC view. The measurement is taken by placing four calipers around the abdomen on the skin edge, not the rib cage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52505 \" href=\"mobipreview.htm?36/43/37556\">",
"     image 7",
"    </a>",
"    ). This will improve test performance while reducing the risk of underestimation of the AC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. The ultrasound machine will approximate the abdominal circumference. Another method is to use the electronic ellipse function on the ultrasound machine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other biometric parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other less commonly used biometric parameters include the intra- and interorbital diameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/80\">",
"     80",
"    </a>",
"    ], transverse cerebellar diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/81-83\">",
"     81-83",
"    </a>",
"    ], clavicle length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/84\">",
"     84",
"    </a>",
"    ], foot length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], and length of long bones of the extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20,69,80,84,85,87-89\">",
"     20,69,80,84,85,87-89",
"    </a>",
"    ]. These measures tend to have slightly wider ranges of variability in comparison to standard parameters during the early second trimester, and, once again, there is marked variability late in the gestation. Therefore, the value of these additional measurements is questionable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Use of multiple markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimation of gestational age based on one parameter may be significantly different from that calculated from the others. A thorough evaluation is warranted to determine the etiology of the abnormal measurement. As an example, there may be a fetal abnormality such as hydrocephalus distorting the HC or BPD. Various fetal body ratio indexes (eg,",
"    <span class=\"nowrap\">",
"     HC/AC,",
"    </span>",
"    <span class=\"nowrap\">",
"     BPD/FL,",
"    </span>",
"    <span class=\"nowrap\">",
"     FL/AC)",
"    </span>",
"    have been established across pregnancy to define how these measurements correlate in an average fetus and to determine if a parameter is potentially abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/62,63,90-93\">",
"     62,63,90-93",
"    </a>",
"    ]. After a careful assessment, it is usually appropriate to omit a single discordant parameter from the gestational age calculation.",
"   </p>",
"   <p>",
"    Human error and normal variation in fetal size can result in over- or under-estimation of gestational age. Regression equations using the four standard biometric parameters minimize, but do not eliminate, these problems and yield the best estimation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The ideal biometric assessment incorporates the least number of images with the highest potential for accuracy. When multiple biometric parameters were compared, the best test performance with the least variability was obtained with the four standard biometric measures (BPD, HC, FL, and AC) described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/65,67\">",
"     65,67",
"    </a>",
"    ]. A two biometric parameter (HC and FL) approach showed similar test performance as the four parameter approach for predicting gestational age in the first half of pregnancy, but variability was slightly higher later in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/54,67,75\">",
"     54,67,75",
"    </a>",
"    ]. The addition of a fifth parameter, such as length of the radius, did not further improve test performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/67\">",
"     67",
"    </a>",
"    ]. Therefore, the four measures of BPD, HC, FL, and AC has remained the standard formula for estimating gestational age in the second and third trimesters.",
"   </p>",
"   <p>",
"    Additional measurements may be useful when there are biometric discrepancies. If the four routine parameters do not correlate, choosing which measurements are most accurate for dating purposes can be a difficult task; therefore, incorporating extra parameters to assist in making an educated estimate may be useful in this setting. As an example, the transverse cerebellar diameter (in millimeters) correlates with gestational age up to 22 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/81\">",
"     81",
"    </a>",
"    ]. When standard biometry is inconclusive, this additional measurement may help to clarify the situation. However, as with all parameters discussed, the accuracy of additional measurements is age-dependent with significant variability in late pregnancy.",
"   </p>",
"   <p>",
"    A potential source of bias is when the ultrasound screen displays the calculated gestational age next to each biometric measurement. The sonographer may adjust the position of the cursors to fit the expected fetal age as opposed to the actual anatomic reference points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SIGNS OF FETAL MATURITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several signs suggestive of fetal maturity that can be observed sonographically and correlated with gestational age when an early ultrasound examination has not been performed or menstrual dates are unknown or uncertain. As an example, the femoral epiphyseal and proximal tibial ossification centers are well visualized by 32 and 35 weeks gestational age, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/94-98\">",
"     94-98",
"    </a>",
"    ]. The proximal humeral epiphysis also appears in the late third trimester and correlates with fetal lung maturity and gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Identification of such landmarks suggests the fetus has most likely attained these milestones in the third trimester. These findings of the bony skeleton cannot be incorporated into actual biometric evaluation of gestational age; they are merely visual aides to help establish fetal maturity in late pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ASSIGNING THE EDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard deviations of biometric measurements taken from normal pregnancies increase as pregnancy progresses. Thus, fetal biometric images are most useful for obtaining an accurate estimate of fetal age when performed in the first 20 weeks of pregnancy, with a reasonably accurate estimation as late as 28 weeks. The range of error in predicting delivery dates by ultrasound examinations is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78859 \" href=\"mobipreview.htm?26/55/27515\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/29,33,35,36,38\">",
"     29,33,35,36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A practical approach to assigning EDD is to use the sonographically derived gestational age to calculate EDD if it differs from that calculated using the LMP by more than seven days in the first trimester and by more than 10 days in the second trimester but before 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, the 95% CI for the gestational age estimate can be derived by using a constant error of &plusmn;8 percent (2 standard deviations) of the estimate or by reporting variability in terms of specific days (&plusmn;2 to &plusmn;11 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, if the sonographically-based EDD differs from the menstrually-based EDD by more than 8 percent, then the sonographically-based EDD should be used.",
"   </p>",
"   <p>",
"    Clinicians should be particularly cautious when changing the EDD based upon measurements obtained from an ultrasound examination performed late in pregnancy. A single late examination cannot reliably distinguish between a pregnancy that is misdated and younger than expected, and a pregnancy that is complicated by fetal growth restriction. Late pregnancy ultrasound measurements should never be used to change an EDD established by an examination performed earlier in pregnancy.",
"   </p>",
"   <p>",
"    After 28 weeks of gestation, it is inappropriate to rely solely on a single set of the usual biometric parameters for fetal dating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/20\">",
"     20",
"    </a>",
"    ]. When menstrual dates are discordant with the gestational age suggested by a late pregnancy sonographic examination, serial measurements showing accelerated or restricted growth over weeks may help to differentiate macrosomic and growth restricted fetuses from those with inaccurate menstrual dating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/102\">",
"     102",
"    </a>",
"    ]. Thus, serial examinations may provide more accurate information and allow the physician to make a more reliable clinical assessment. Because of measurement variability, these serial examinations should be spaced by an interval of at least two weeks.",
"   </p>",
"   <p>",
"    In some cases, early fetal growth restriction rather than inaccurate menstrual dating may be the reason for a discrepancy between ultrasound and menstrual dating (or dating based on conception using assisted reproductive technologies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/54\">",
"     54",
"    </a>",
"    ], although this is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/47/34553/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. When an EDD is revised because of smaller than expected size of the fetus on a second ultrasound examination, we suggest a follow-up ultrasound to evaluate fetal growth over time and make sure this finding was not due to early growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Test performance of various biometric measurements for determination of gestational age is shown in the table (",
"      <a class=\"graphic graphic_table graphicRef78859 \" href=\"mobipreview.htm?26/55/27515\">",
"       table 1",
"      </a>",
"      ). It is reasonable to use the sonographically derived estimated date of delivery (EDD) if it differs from that calculated using the last menstrual period (LMP) by more than five to seven days in the first trimester and by more than 10 to 14 days in the second trimester or by 8 percent. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Assigning the EDD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gestational sac is the earliest sonographic landmark of pregnancy (",
"      <a class=\"graphic graphic_table graphicRef83304 \" href=\"mobipreview.htm?4/2/4139\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'First trimester'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to visualization of the embryo at five to six weeks menstrual age, measurement of the gestational sac diameter (MSD) allows estimation of gestational age. The sum of 30 and the sac size in millimeters is equivalent to the gestational age in days. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Gestational sac'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the embryonic or fetal pole can be visualized, measurement of crown-rump length (CRL) is",
"      <strong>",
"       the most accurate method of pregnancy dating",
"      </strong>",
"      (&plusmn;3 days) at 7 to 10 weeks of gestation. However, after 10 weeks of gestation, the accuracy of the CRL falls with a margin of error of &plusmn;5 days at 10 to 14 weeks and &plusmn;8.4 days by the 15th week. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Crown rump length'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the early second trimester, the biometric measurements of choice are the biparietal diameter (BPD), head circumference (HC), femur length (FL), and abdominal circumference (AC). Prior to 20 weeks, they can be used to estimate gestational age with an accuracy of within one week, but this falls to three to four weeks near term. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Use of multiple markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnancies with an unknown or uncertain last menstrual period and late first sonogram, ossification of the distal femoral epiphysis suggests a fetal age of at least 32 weeks and ossification of the proximal tibial and humeral epiphyses suggests a fetal age of at least 35 weeks. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Signs of fetal maturity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/1\">",
"      Mongelli M, Wilcox M, Gardosi J. Estimating the date of confinement: ultrasonographic biometry versus certain menstrual dates. Am J Obstet Gynecol 1996; 174:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/2\">",
"      Neilson JP. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev 2000; :CD000182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/3\">",
"      Yang H, Kramer MS, Platt RW, et al. How does early ultrasound scan estimation of gestational age lead to higher rates of preterm birth? Am J Obstet Gynecol 2002; 186:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/4\">",
"      Bennett KA, Crane JM, O'shea P, et al. First trimester ultrasound screening is effective in reducing postterm labor induction rates: a randomized controlled trial. Am J Obstet Gynecol 2004; 190:1077.",
"     </a>",
"    </li>",
"    <li>",
"     Laing, FC, Frates, MC. Ultrasound Evaluation During the First Trimester of Pregnancy. In: Ultrasonography in Obstetrics and Gynecology, 4th ed, Callen, PW (Ed), WB Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/6\">",
"      Rowling SE, Langer JE, Coleman BG, et al. Sonography during early pregnancy: dependence of threshold and discriminatory values on transvaginal transducer frequency. AJR Am J Roentgenol 1999; 172:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/7\">",
"      Grisolia G, Milano K, Pilu G, et al. Biometry of early pregnancy with transvaginal sonography. Ultrasound Obstet Gynecol 1993; 3:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/8\">",
"      Fleischer AC, Kalemeris GC, Machin JE, et al. Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J Ultrasound Med 1986; 5:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/9\">",
"      Forrest TS, Elyaderani MK, Muilenburg MI, et al. Cyclic endometrial changes: US assessment with histologic correlation. Radiology 1988; 167:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/10\">",
"      Nyberg DA, Laing FC, Filly RA. Threatened abortion: sonographic distinction of normal and abnormal gestation sacs. Radiology 1986; 158:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/11\">",
"      Timor-Tritsch IE, Farine D, Rosen MG. A close look at early embryonic development with the high-frequency transvaginal transducer. Am J Obstet Gynecol 1988; 159:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/12\">",
"      Rossavik IK, Torjusen GO, Gibbons WE. Conceptual age and ultrasound measurements of gestational sac and crown-rump length in in vitro fertilization pregnancies. Fertil Steril 1988; 49:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/13\">",
"      de Crespigny LC, Cooper D, McKenna M. Early detection of intrauterine pregnancy with ultrasound. J Ultrasound Med 1988; 7:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/14\">",
"      Wong HS, Cheung YK, Tait J. Sonographic study of the decidua basalis in the first trimester of pregnancy. Ultrasound Obstet Gynecol 2009; 33:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/15\">",
"      Nyberg DA, Mack LA, Laing FC, Patten RM. Distinguishing normal from abnormal gestational sac growth in early pregnancy. J Ultrasound Med 1987; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/16\">",
"      Robinson HP. \"Gestation sac\" volumes as determined by sonar in the first trimester of pregnancy. Br J Obstet Gynaecol 1975; 82:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/17\">",
"      Daya S, Woods S, Ward S, et al. Early pregnancy assessment with transvaginal ultrasound scanning. CMAJ 1991; 144:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/18\">",
"      Hellman LM, Kobayashi M, Fillisti L, et al. Growth and development of the human fetus prior to the twentieth week of gestation. Am J Obstet Gynecol 1969; 103:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/19\">",
"      Nyberg DA, Filly RA, Mahony BS, et al. Early gestation: correlation of HCG levels and sonographic identification. AJR Am J Roentgenol 1985; 144:951.",
"     </a>",
"    </li>",
"    <li>",
"     Filly, RA, Hadlock, FP. Sonographic Determination of Menstrual Age. In: Ultrasonography in Obstetrics and Gynecology, 4th ed, Callen, PW (Ed), WB Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/21\">",
"      Levi CS, Lyons EA, Lindsay DJ. Early diagnosis of nonviable pregnancy with endovaginal US. Radiology 1988; 167:383.",
"     </a>",
"    </li>",
"    <li>",
"     Benson, CB, Doubilet, PM. Fetal measurements-normal and abnormal fetal growth. In: Diagnostic Ultrasound, Vol 2, 2nd ed, Rumack, CM, Wilson, SR, Charboneau, JW (Eds), CV Mosby, St. Louis 1998. p.1013.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/23\">",
"      Lindsay DJ, Lovett IS, Lyons EA, et al. Yolk sac diameter and shape at endovaginal US: predictors of pregnancy outcome in the first trimester. Radiology 1992; 183:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/24\">",
"      Stampone C, Nicotra M, Muttinelli C, Cosmi EV. Transvaginal sonography of the yolk sac in normal and abnormal pregnancy. J Clin Ultrasound 1996; 24:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/25\">",
"      Jauniaux E, Jurkovic D, Henriet Y, et al. Development of the secondary human yolk sac: correlation of sonographic and anatomical features. Hum Reprod 1991; 6:1160.",
"     </a>",
"    </li>",
"    <li>",
"     Nyberg, DA, Hill, LM. Normal early intrauterine pregnancy: Sonographic development and hCG correlation. In Transvaginal Ultrasound, Nyberg, DA, Hill, LM, Bohm-Velez, M, Mendelson, EB (Eds), Mosby-Year Book, St. Louis 1992. p.65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/27\">",
"      Cadkin AV, McAlpin J. Detection of fetal cardiac activity between 41 and 43 days of gestation. J Ultrasound Med 1984; 3:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/28\">",
"      Nyberg DA, Mack LA, Harvey D, Wang K. Value of the yolk sac in evaluating early pregnancies. J Ultrasound Med 1988; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/29\">",
"      Goldstein SR, Wolfson R. Endovaginal ultrasonographic measurement of early embryonic size as a means of assessing gestational age. J Ultrasound Med 1994; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/30\">",
"      Yeh HC, Rabinowitz JG. Endovaginal ultrasonographic measurement of early embryonic size. J Ultrasound Med 1995; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/31\">",
"      Daya S. Accuracy of gestational age estimation by means of fetal crown-rump length measurement. Am J Obstet Gynecol 1993; 168:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/32\">",
"      Wisser J, Dirschedl P, Krone S. Estimation of gestational age by transvaginal sonographic measurement of greatest embryonic length in dated human embryos. Ultrasound Obstet Gynecol 1994; 4:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/33\">",
"      Robinson HP, Fleming JE. A critical evaluation of sonar \"crown-rump length\" measurements. Br J Obstet Gynaecol 1975; 82:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/34\">",
"      Deter RL, Buster JE, Casson PR, Carson SA. Individual growth patterns in the first trimester: evidence for difference in embryonic and fetal growth rates. Ultrasound Obstet Gynecol 1999; 13:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/35\">",
"      Robinson, HP. Sonar measurement of fetal crown-rump length as a means of assessing maturity in first trimester of pregnancy. BMJ 1973; 4:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/36\">",
"      Hadlock FP, Shah YP, Kanon DJ, Lindsey JV. Fetal crown-rump length: reevaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US. Radiology 1992; 182:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/37\">",
"      Silva PD, Mahairas G, Schaper AM, Schauberger CW. Early crown-rump length. A good predictor of gestational age. J Reprod Med 1990; 35:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/38\">",
"      Drumm JE, Clinch J, MacKenzie G. The ultrasonic measurement of fetal crown-rump length as a method of assessing gestational age. Br J Obstet Gynaecol 1976; 83:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/39\">",
"      MacGregor SN, Tamura RK, Sabbagha RE, et al. Underestimation of gestational age by conventional crown-rump length dating curves. Obstet Gynecol 1987; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     Jeanty, P. Fetal Biometry. In: Sonography in Obstetrics and Gynecology &ndash; Principles and Practice, 6th edition, Fleischer, AC, Manning, FA, Jeanty, P, Romero, R (Eds), McGraw-Hill, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/41\">",
"      Campbell S, Warsof SL, Little D, Cooper DJ. Routine ultrasound screening for the prediction of gestational age. Obstet Gynecol 1985; 65:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/42\">",
"      Waldenstr&ouml;m U, Axelsson O, Nilsson S. A comparison of the ability of a sonographically measured biparietal diameter and the last menstrual period to predict the spontaneous onset of labor. Obstet Gynecol 1990; 76:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/43\">",
"      Hackmon R, Le Scale KB, Horani J, et al. Is severe macrosomia manifested at 11-14 weeks of gestation? Ultrasound Obstet Gynecol 2008; 32:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/44\">",
"      Hadlock FP. Sonographic estimation of fetal age and weight. Radiol Clin North Am 1990; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/45\">",
"      Reece EA, Scioscia AL, Green J, et al. Embryonic trunk circumference: a new biometric parameter for estimation of gestational age. Am J Obstet Gynecol 1987; 156:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/46\">",
"      Selbing A. Gestational age and ultrasonic measurement of gestational sac, crown-rump length and biparietal diameter during first 15 weeks of pregnancy. Acta Obstet Gynecol Scand 1982; 61:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/47\">",
"      Bovicelli L, Orsini LF, Rizzo N, et al. Estimation of gestational age during the first trimester by real-time measurement of fetal crown-rump length and biparietal diameter. J Clin Ultrasound 1981; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/48\">",
"      Hadlock FP, Harrist RB, Martinez-Poyer J. How accurate is second trimester fetal dating? J Ultrasound Med 1991; 10:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/49\">",
"      Rossavik IK, Fishburne JI. Conceptional age, menstrual age, and ultrasound age: a second-trimester comparison of pregnancies of known conception date with pregnancies dated from the last menstrual period. Obstet Gynecol 1989; 73:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/50\">",
"      de Crespigny, LC, Speirs, AL. A new look at biparietal diameter. Aust N Z J Obstet Gynaecol 1989; 29:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/51\">",
"      Hadlock FP, Deter RL, Harrist RB, Park SK. Fetal biparietal diameter: rational choice of plane of section for sonographic measurement. AJR Am J Roentgenol 1982; 138:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/52\">",
"      Kurtz AB, Wapner RJ, Kurtz RJ, et al. Analysis of biparietal diameter as an accurate indicator of gestational age. J Clin Ultrasound 1980; 8:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/53\">",
"      Kopta MM, May RR, Crane JP. A comparison of the reliability of the estimated date of confinement predicted by crown-rump length and biparietal diameter. Am J Obstet Gynecol 1983; 145:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/54\">",
"      Persson PH, Weldner BM. Reliability of ultrasound fetometry in estimating gestational age in the second trimester. Acta Obstet Gynecol Scand 1986; 65:481.",
"     </a>",
"    </li>",
"    <li>",
"     Kurtz, AB, Needleman, L. Ultrasound Assessment of Fetal Age, 2nd Ed, WB Saunders, Philadelphia 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/56\">",
"      Selbing A, Kjessler B. Conceptual dating by ultrasonic measurement of the fetal biparietal diameter in early pregnancy. Acta Obstet Gynecol Scand 1985; 64:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/57\">",
"      Benson CB, Doubilet PM. Sonographic prediction of gestational age: accuracy of second- and third-trimester fetal measurements. AJR Am J Roentgenol 1991; 157:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/58\">",
"      Shepard M, Filly RA. A standardized plane for biparietal diameter measurement. J Ultrasound Med 1982; 1:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/59\">",
"      Hadlock FP, Deter RL, Harrist RB, Park SK. Fetal biparietal diameter: a critical re-evaluation of the relation to menstrual age by means of real-time ultrasound. J Ultrasound Med 1982; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/60\">",
"      Wolfson RN, Zador IE, Halvorsen P, et al. Biparietal diameter in premature rupture of membranes: errors in estimating gestational age. J Clin Ultrasound 1983; 11:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/61\">",
"      O'Keeffe DF, Garite TJ, Elliott JP, Burns PE. The accuracy of estimated gestational age based on ultrasound measurement of biparietal diameter in preterm premature rupture of the membranes. Am J Obstet Gynecol 1985; 151:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/62\">",
"      Hadlock FP, Deter RL, Carpenter RJ, Park SK. Estimating fetal age: effect of head shape on BPD. AJR Am J Roentgenol 1981; 137:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/63\">",
"      Gray DL, Songster GS, Parvin CA, Crane JP. Cephalic index: a gestational age-dependent biometric parameter. Obstet Gynecol 1989; 74:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/64\">",
"      Law RG, MacRae KD. Head circumference as an index of fetal age. J Ultrasound Med 1982; 1:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/65\">",
"      Hadlock FP, Deter RL, Harrist RB, Park SK. Estimating fetal age: computer-assisted analysis of multiple fetal growth parameters. Radiology 1984; 152:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/66\">",
"      Hadlock FP, Harrist RB, Shah YP, et al. Estimating fetal age using multiple parameters: a prospective evaluation in a racially mixed population. Am J Obstet Gynecol 1987; 156:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/67\">",
"      Hill LM, Guzick D, Hixson J, et al. Composite assessment of gestational age: a comparison of institutionally derived and published regression equations. Am J Obstet Gynecol 1992; 166:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/68\">",
"      Ott WJ. The use of ultrasonic fetal head circumference for predicting expected date of confinement. J Clin Ultrasound 1984; 12:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/69\">",
"      Jeanty P, Rodesch F, Delbeke D, Dumont JE. Estimation of gestational age from measurements of fetal long bones. J Ultrasound Med 1984; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/70\">",
"      Ott WJ. Accurate gestational dating. Obstet Gynecol 1985; 66:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/71\">",
"      Hadlock FP, Harrist RB, Deter RL, Park SK. Fetal femur length as a predictor of menstrual age: sonographically measured. AJR Am J Roentgenol 1982; 138:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/72\">",
"      Hohler CW, Quetel TA. Fetal femur length: equations for computer calculation of gestational age from ultrasound measurements. Am J Obstet Gynecol 1982; 143:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/73\">",
"      Goldstein RB, Filly RA, Simpson G. Pitfalls in femur length measurements. J Ultrasound Med 1987; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/74\">",
"      Mahony BS, Filly RA. High-resolution sonographic assessment of the fetal extremities. J Ultrasound Med 1984; 3:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/75\">",
"      Hadlock FP, Harrist RB, Deter RL, Park SK. A prospective evaluation of fetal femur length as a predictor of gestational age. J Ultrasound Med 1983; 2:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/76\">",
"      Papageorghiou AT, Fratelli N, Leslie K, et al. Outcome of fetuses with antenatally diagnosed short femur. Ultrasound Obstet Gynecol 2008; 31:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/77\">",
"      Weisz B, David AL, Chitty L, et al. Association of isolated short femur in the mid-trimester fetus with perinatal outcome. Ultrasound Obstet Gynecol 2008; 31:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/78\">",
"      Hadlock FP, Deter RL, Harrist RB, Park SK. Fetal abdominal circumference as a predictor of menstrual age. AJR Am J Roentgenol 1982; 139:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/79\">",
"      Chinn DH, Filly RA, Callen PW. Ultrasonic evaluation of fetal umbilical and hepatic vascular anatomy. Radiology 1982; 144:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/80\">",
"      Jeanty P, Cantraine F, Cousaert E, et al. The binocular distance: a new way to estimate fetal age. J Ultrasound Med 1984; 3:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/81\">",
"      Hill LM, Guzick D, Fries J, et al. The transverse cerebellar diameter in estimating gestational age in the large for gestational age fetus. Obstet Gynecol 1990; 75:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/82\">",
"      Reece EA, Goldstein I, Pilu G, Hobbins JC. Fetal cerebellar growth unaffected by intrauterine growth retardation: a new parameter for prenatal diagnosis. Am J Obstet Gynecol 1987; 157:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/83\">",
"      Chavez MR, Ananth CV, Smulian JC, et al. Fetal transcerebellar diameter measurement with particular emphasis in the third trimester: a reliable predictor of gestational age. Am J Obstet Gynecol 2004; 191:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/84\">",
"      Yarkoni S, Schmidt W, Jeanty P, et al. Clavicular measurement: a new biometric parameter for fetal evaluation. J Ultrasound Med 1985; 4:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/85\">",
"      Mercer BM, Sklar S, Shariatmadar A, et al. Fetal foot length as a predictor of gestational age. Am J Obstet Gynecol 1987; 156:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/86\">",
"      Platt LD, Medearis AL, DeVore GR, et al. Fetal foot length: relationship to menstrual age and fetal measurements in the second trimester. Obstet Gynecol 1988; 71:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/87\">",
"      Hill LM, Guzick D, Thomas ML, Fries JK. Fetal radius length: a critical evaluation of race as a factor in gestational age assessment. Am J Obstet Gynecol 1989; 161:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/88\">",
"      Hill LM, Guzick D, Rivello D, et al. The transverse cerebellar diameter cannot be used to assess gestational age in the small for gestational age fetus. Obstet Gynecol 1990; 75:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/89\">",
"      Mayden KL, Tortora M, Berkowitz RL, et al. Orbital diameters: a new parameter for prenatal diagnosis and dating. Am J Obstet Gynecol 1982; 144:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/90\">",
"      Hadlock FP, Deter RL, Harrist RB, et al. A date-independent predictor of intrauterine growth retardation: femur length/abdominal circumference ratio. AJR Am J Roentgenol 1983; 141:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/91\">",
"      Hadlock FP, Harrist RB, Shah Y, Park SK. The femur length/head circumference relation in obstetric sonography. J Ultrasound Med 1984; 3:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/92\">",
"      Hadlock FP, Harrist RB, Martinez-Poyer J. Fetal body ratios in second trimester: a useful tool for identifying chromosomal abnormalities? J Ultrasound Med 1992; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/93\">",
"      Hohler CW, Quetel TA. Comparison of ultrasound femur length and biparietal diameter in late pregnancy. Am J Obstet Gynecol 1981; 141:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/94\">",
"      Chinn DH, Bolding DB, Callen PW, et al. Ultrasonographic identification of fetal lower extremity epiphyseal ossification centers. Radiology 1983; 147:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/95\">",
"      Mahony BS, Callen PW, Filly RA. The distal femoral epiphyseal ossification center in the assessment of third-trimester menstrual age: sonographic identification and measurement. Radiology 1985; 155:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/96\">",
"      Mahony BS, Bowie JD, Killam AP, et al. Epiphyseal ossification centers in the assessment of fetal maturity: sonographic correlation with the amniocentesis lung profile. Radiology 1986; 159:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/97\">",
"      Reece EA, Gabrielli S, Degennaro N, Hobbins JC. Dating through pregnancy: a measure of growing up. Obstet Gynecol Surv 1989; 44:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/98\">",
"      Goldstein I, Reece EA, O'Connor TZ, Hobbins JC. Estimating gestational age in the term pregnancy with a model based on multiple indices of fetal maturity. Am J Obstet Gynecol 1989; 161:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/99\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 97: Fetal lung maturity. Obstet Gynecol 2008; 112:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/100\">",
"      Abuhamad AZ, ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin, clinical management guidelines for obstetrician-gynecologists number 98, October 2008 (replaces Practice Bulletin number 58, December 2004). Ultrasonography in pregnancy. Obstet Gynecol 2008; 112:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/101\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 101: Ultrasonography in pregnancy. Obstet Gynecol 2009; 113:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/102\">",
"      Sholl JS, Woo D, Rubin JM, et al. Intrauterine growth retardation risk detection for fetuses of unknown gestational age. Am J Obstet Gynecol 1982; 144:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/103\">",
"      Smith GC, Smith MF, McNay MB, Fleming JE. First-trimester growth and the risk of low birth weight. N Engl J Med 1998; 339:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/104\">",
"      Henriksen TB, Wilcox AJ, Hedegaard M, Secher NJ. Bias in studies of preterm and postterm delivery due to ultrasound assessment of gestational age. Epidemiology 1995; 6:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/47/34553/abstract/105\">",
"      Morin I, Morin L, Zhang X, et al. Determinants and consequences of discrepancies in menstrual and ultrasonographic gestational age estimates. BJOG 2005; 112:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5391 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34553=[""].join("\n");
var outline_f33_47_34553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Naegele's rule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Calculator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Uterine size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SONOGRAPHIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      First trimester",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gestational sac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Yolk sac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Crown rump length",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cardiac activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Second and third trimester",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Biparietal diameter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cephalic index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Head circumference",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Femur length",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Abdominal circumference",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other biometric parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Use of multiple markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SIGNS OF FETAL MATURITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ASSIGNING THE EDD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5391|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/41/39572\" title=\"diagnostic image 1\">",
"      Yolk sac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/5/11351\" title=\"diagnostic image 2\">",
"      Gestational sac and embryo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/61/18387\" title=\"diagnostic image 3\">",
"      Fetal BPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/62/30689\" title=\"diagnostic image 4\">",
"      Cavum septum pellucidum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/16/33027\" title=\"diagnostic image 5\">",
"      Fetal femur length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/29/9681\" title=\"diagnostic image 6\">",
"      Sonogram fetal abd circumferenc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/43/37556\" title=\"diagnostic image 7\">",
"      Fetal abdominal diameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5391|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/55/27515\" title=\"table 1\">",
"      Assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/2/4139\" title=\"table 2\">",
"      Timing of first ultrasound appearance of pregnancy landmarks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?41/5/42067?source=related_link\" title=\"calculator 1\">",
"      Calculator: Estimated Date of Delivery (EDD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?8/55/9074?source=related_link\" title=\"calculator 2\">",
"      Calculator: Gestational age from Estimated Date of Delivery (EDD)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5783?source=related_link\">",
"      Diagnosis and outcome of first trimester growth delay",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/25?source=related_link\">",
"      Prenatal sonographic assessment of fetal weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_47_34554="Scapular motion";
var content_f33_47_34554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Scapular motion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 867px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Boldface indicates prime or essential mover(s). Numbers refer to the figure.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      The glenoid cavity moves superiorly, as in abduction of the arm.",
"      <br>",
"       &Delta; The glenoid cavity moves inferiorly, as in adduction of the arm.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34554=[""].join("\n");
var outline_f33_47_34554=null;
var title_f33_47_34555="Other factors and ADH release";
var content_f33_47_34555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors regulating the release of ADH",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Stimuli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperosmolality",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypovolemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stress (eg, pain)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nausea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoglycemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nicotine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Morphine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other drugs",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoosmolality",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypervolemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Physiologic and pathologic factors affecting the release of antidiuretic hormone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34555=[""].join("\n");
var outline_f33_47_34555=null;
var title_f33_47_34556="Classification of pediatric hemorrhage shock";
var content_f33_47_34556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of hemorrhagic shock in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class I, very mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class II, mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class III, moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class IV, severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent blood volume loss",
"       </td>",
"       <td>",
"        &lt;15 percent",
"       </td>",
"       <td>",
"        15-30 percent",
"       </td>",
"       <td>",
"        30-40 percent",
"       </td>",
"       <td>",
"        &gt;40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Slightly increased",
"       </td>",
"       <td>",
"        Moderately increased",
"       </td>",
"       <td>",
"        Markedly increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory rate",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Slightly increased",
"       </td>",
"       <td>",
"        Moderately increased",
"       </td>",
"       <td>",
"        Markedly increased, markedly decreased, or absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood pressure",
"       </td>",
"       <td>",
"        Normal or slightly increased",
"       </td>",
"       <td>",
"        Normal or slightly decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulses",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal or decreased peripheral",
"       </td>",
"       <td>",
"        Weak or absent peripheral",
"       </td>",
"       <td>",
"        Absent peripheral, weak or absent central",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        Warm and pink",
"       </td>",
"       <td>",
"        Cool extremities, mottled",
"       </td>",
"       <td>",
"        Cool mottling extremities, or pallor",
"       </td>",
"       <td>",
"        Cold extremities with pallor or cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capillary refill",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"       <td>",
"        Markedly prolonged",
"       </td>",
"       <td>",
"        Markedly prolonged",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mental status",
"       </td>",
"       <td>",
"        Slightly anxious",
"       </td>",
"       <td>",
"        Mildly anxious, confused, combative",
"       </td>",
"       <td>",
"        Very anxious, confused, or lethargic",
"       </td>",
"       <td>",
"        Very confused, lethargic, or comatose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine output",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Slightly decreased",
"       </td>",
"       <td>",
"        Moderately decreased",
"       </td>",
"       <td>",
"        Markedly decreased or anuria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hazinski, MF, Barkin, RM. Shock. In: Pediatric emergency medicine: Concepts and clinical practice, Barkin, RM (Ed), Mosby-Yearbook Inc, St. Louis, MO 1997. p. 118; and Waltzman, ML, Mooney, DP. Major trauma. In: Textbook of Pediatric Emergency Medicine, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p. 1354.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34556=[""].join("\n");
var outline_f33_47_34556=null;
var title_f33_47_34557="Evaluation of transverse myelitis";
var content_f33_47_34557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential medical work-up for suspected acute transverse myelitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indicative signs and symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Infectious etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever",
"       </td>",
"       <td>",
"        CSF Gram's stain and bacterial culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningismus",
"       </td>",
"       <td>",
"        CSF PCR: HSV-1, HSV-2, HHV-6, VZV, CMV, EBV, enteroviruses, HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rash",
"       </td>",
"       <td>",
"        CSF viral culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Concurrent systemic infection",
"       </td>",
"       <td>",
"        CSF acid-fast bacilli smear and tuberculous culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunocompromised state",
"       </td>",
"       <td>",
"        CSF HSV, VZV, and HTLV-1 antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent genital infection",
"       </td>",
"       <td>",
"        CSF anti-",
"        <em>",
"         Borrelia burgdorferi",
"        </em>",
"        antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Symptoms of zoster radiculopathy",
"       </td>",
"       <td>",
"        CSF VDRL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenopathy",
"       </td>",
"       <td>",
"        CSF India ink and fungal culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Residence in area endemic for parasitic infections",
"       </td>",
"       <td>",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serology for antibodies to HSV, VZV, HTLV-1,",
"        <em>",
"         B. burgdorferi",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serology for hepatitis A, B, C, and",
"        <em>",
"         Mycoplasma",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider serology for parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Systemic inflammatory disease (vasculitis, collagen vascular diseases, mixed connective tissue disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rash",
"       </td>",
"       <td>",
"        Serum ACE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oral or genital ulcers",
"       </td>",
"       <td>",
"        Auto-antibodies: ANA, ds-DNA, SS-A (Ro), SS-B (La), Sm (Smith), RNP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenopathy",
"       </td>",
"       <td>",
"        Complement levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Livedo reticularis",
"       </td>",
"       <td>",
"        Urinalysis with microscopic analysis for hematuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serositis",
"       </td>",
"       <td>",
"        Lip/salivary gland biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Photosensitivity",
"       </td>",
"       <td>",
"        Chest CT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory arthritis",
"       </td>",
"       <td>",
"        Schirmer's test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythema nodosum",
"       </td>",
"       <td>",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Xerostomia",
"       </td>",
"       <td rowspan=\"7\">",
"        Anti-phospholipid antibodies (anti-cardiolipin antibodies, Russel viper venom time, partial thromboplastin time)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contractures or thickening of skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anemia/leukopenia/thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raynaud's phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History of arterial and venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        MS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Previous demyelination event",
"       </td>",
"       <td>",
"        Brain MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Incomplete deficit clinically with MRI abnormality &le;2 spinal segments and &lt;50 percent of cord diameter",
"       </td>",
"       <td rowspan=\"2\">",
"        Evoked potentials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CSF oligoclonal bands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neuromyelitis optica (Devic's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Optic neuritis",
"       </td>",
"       <td>",
"        Evoked potentials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Normal brain MRI",
"       </td>",
"       <td>",
"        Brain MRI (usually negative)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of multiple autoantibodies, of the type listed above or others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Idiopathic transverse myelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        No clinical or paraclinical features suggestive of another diagnostic category",
"       </td>",
"       <td>",
"        Evoked potentials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electromyography/nerve conduction velocity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HSV: herpes simplex virus; HHV: human herpes virus; VZV: varicella zoster virus; CMV: cytomegalovirus; EBV: Epstein-Barr virus; HTLV-1: human T-cell lymphotropic virus-1; VDRL: Veneral Disease Research Laboratory; ACE: angiotensin-converting enzyme; ANA: anti-nuclear antibodies; ds: double-stranded; RNP: ribonucleoprotein.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59:499. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34557=[""].join("\n");
var outline_f33_47_34557=null;
var title_f33_47_34558="Algorithm for the diagnosis of AMR with allo dysfunction";
var content_f33_47_34558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for the diagnosis of antibody-mediated rejection of renal allograft with renal dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 450px; background-image: url(data:image/gif;base64,R0lGODlhrwHCAcQAAP///4CAgH9/fz8/P7+/vwAAAO/v7y8vL8/Pz9/f35+fn19fX09PTx8fH0BAQK+vr4+Pj29vb8DAwA8PD6CgoODg4GBgYLCwsCAgIDAwMHBwcNDQ0BAQEJCQkFBQUAAAACH5BAAAAAAALAAAAACvAcIBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlmoUAZqbnJ2en6ChoqOkpZ4Ul6l9DgsCrq+wsbKztLW2t7i5sAsOqr55DgR/BL2/xnTBw8XHzG/JfsTN0m3PfdHT2GjVfNfZ3mPbe93f5F7hBgTpUwYLAwg0DwMRKOPl9lnhBA0CEQcGUQsgAPgnI0EDAwYGCCtR755DKvkGiIggIIECAgIGtssIQMAABu/YDeCo4AEDBglE/3hc8C4eyBIJ2ikAYLAViZgjhaVToADnSwH7FDSwSaLhw6NPIooISGACg4wHhFGEwAAAggcAogKgCECeAQgLtoa9atKAQYIiGhAwwECBgQMQForQalPAhAg93yFoAEBBVARw5YowirSwknz7FvgjINHqPgEyDyjQ+7hdV50SJ6Bl0AqoXASNCVRVSAKwyoyuRihoVwAAYxGkGS4zTPuwYNd/B4eOmu4dgQj7CPAm8I7069YjBsRNh/a1a4mxdZ/uyDHCgpStnUcfQbi29yBKuTc2MOGdVQT/4pE3Xxxz15lWBVQdmHKE5o4Ct5P/xzV1V6wJZNfYAFjJ9t2BRYQnnf8IgA1wgAAPHOCgXhI+eNlzVg2gIVb9OFifCBEesMA/2/V1AAMjUcdgA/IICKKEBiIoIxDheEHQAvDV0N2MPNJQYxeKHTDPDTv2aOQLP+JR5JFMqpDkHUs2KWUJT7aAwJArIICiDej9EOWUYFbJgnMrNNBlDLFFYF4PX4IppZgoGODRlhDUN5lIIxJQgAA8pWQRTQp4JJBVKNY5VEY9uXbSQhAOENYMbbrJJJwncKWARFztx4BADyAQIHHGSaTPWg0kYBB6ELwV12UGmVoqAAXM1Baks0lq6wiUmnDfawb1FdYCDDxQH3KhYngZBFheeCxHAgiEnH8xRHorj7mWgJz/c20dYN5qEwhDrHvaYcQRbAsp5F9qz44Lg7TTylgtCVrFMxiLg02UEXLB9iXqgOnwZdV/5JrW1Tvp0tpuu++OABhnjQHQQIECSDjAP9eyaFm4HUlYVYTQCROxhbBOJwO7B3+XcAq9ikFyybWdjAKOY6zMsmEusyHzzEjVvMbNOD+ksxo893zPz2kELXQ5rOii9NJMN600L0dLmYkpVFcdgAMOWK11KahE7TUPmnwtthphj212GWWfrTYYaa/tdhYYFCB3ARy8bbcVFsxdgAd39y0FBXp34PfgTlSg9waEJ75EBnJjoPjjSGggtwWQV07EBXJ3bfnmP8hdAeeg9+BA/wahl65DABqYrroNG1yw+uuwVz711rTXbjsomsfOTNJO9+7777NArXszRMdc6/C+FK/y8cinonwYRjdPyPNgRC+9INR/Yf31gGTvxfbc+0G0AWt2eWYJarJw/gjp5wB++HwQTSZp7ZdQYqVrJnebjszDH4n8DSNNokTzlJQo5yQfUkkCKpKoObUHAA8YFP/8dwn5PcYzrDpAAt4iDK+AxVojSYBCqGIVrCjkAeUhUv8o6Aj5DUcrIxwSaYpFAuRcxi+TgQ0EzISD97HwDgDU32X8M0P31FCIv9lHVxrgjx6u8IeLCCK5LiOvrHTQiCOwoUK6JK8RNtEGPoQiMvYXrf8AXnErIlLLhcgkAi0SgGPaupBi0GIwMf6PjDsgyKukEEY7xsF7JWCRZKjQRz86A49yKKQhqYHIOChykWsQk0TIdwJKZilZJlhfDDQ5pidCchBias2VTjDKFbDRBOmzIQvSlL8WPPKT2tifS7DSmj+9sR3C+FNHHOWpdrzklA7sSwL0xCd1dEQEl0pRTRCVEgIyKh6PKoonYdm920TILDNxkUcSsBcMWaeE3HSMsURAwquwqgDE8c+1/tEWVV2xVa2ClaxyNJhpUlN8t8lXFjGkTgzdRzWsGaeJcnihgoWMJh5RYmxGyCxniYw79rxn/G6zHW1yxEWqtA52BOoa4GT/hDQGreXDVLRQcU3HoBCVKCLCARkGhew1/XzNAOADGgC5SGHp6Ris/oEsmmTnAEv5aIG2CNSBHRRa9VTpIc6hmBRZtI0YAs2G9tIigcLxgRGLgAFYFAHkNPUpEIQRaT520YcmVamFACQXXolWMKh1C2xtqzkaCYe4ypULb9WCXe+qhbxmYa98xQLvgEfYwi5NeIH1w+xutzWsMbZ2uUvsPdomWbVRtrJmuyxmxabZzXqts549GmhDKwYJPPa0qEWtY1PL2tZWTQL+u5prZ0vb2tr2tqDIWmwDoLvRxs63mwPu64RbOeKqzriPQ27plJs45oLOuYODbnB5+1vqhk+6/33DbnGtO1zuXk+7dgOv2ExritWKArZnI+8ozDsK9L4tACMx7AC8+zX4GtYj9D1bANR1AwHkN2r73YF/7xZgHQxYv/y1wYHfm+AaLHhsBc7Bg9cWYRxMuL4NpsGFESzg/4o2wzPYcGZBLAMRf7jDBCaxwlpgYqFVuL8e5qyKYcPiGPfsxQq28Wdn3JUaW5bHLmgxhlUgrsfQ0wRCxhmOTaChhqUgyQAm8TCF0xsVQJllS9awjqPcAic/ectYBrKPw8tjL6PgyiXLcojB7GIxswDNB1Nzidl8YzevAM7tknMM8DwzPcOAz7fy8wsAnWY7W5nOeTb0l1OMYg4bGNF9Vv/0mSEdaEmfgNBxjm9h52tZTROW03ZTLynYCwr3jk3UoSB1KEzNOfG6zdXNpXR0ZT3d3tLacrC27K23a+vwxW1udVPdr+UW7OblbW58U92x5Zbs5gFuboJT3bPlFu3mGW5uiFPdteWWbekxrgCOe923w309yRWAcq8zN7qvh7kCRLZ07X438jwXO3qHb3S6wzf8UNfb1MGvdboDOGkHTvCCG/zgCJcEqnHL8IZzgtVzWLjDJ35biN/BvvfNuMY3LgtQ2wHjHA+5yIHncT0ImhGYHsPJF5HyM6xcES0Pw8sTEXO0WZoQNf/CzBGRc5XffBA978LODxF0mf9cEEXfwtD/DZF0nYM4HQRIIAxMhb5WsiABEOATHddXyhF8pSInmKTVrYLJO+/a6CmAutRfQHUS1M8FWNd6abaOya+vvceWLEHXx7wHNe8pYhKEAU+UdT8SmIUEEbqIfFSDzqJ4GS47PIEoy85RVSL57GwD8d/hMoPBl1QFhx9B4jEyn740XjwlgLy/rEX2E5zS8iVouhf8Lh0ImMf2I9DloDKSjmV2hSoocb26JvAhgjRIGHL6iJc1Qx7JA2ogHsHLcwTlmj0deQSyxwLtMYR7AHT/+d5XiWuifqjfI1D4JCC+1xkkIeTPafkImYDz/5R86TOG+sS8vkowTwa/pyNfCKAZi3dE/yg0TBLhCu7UFVr1QSaAEdxRVKUxMfSDKF62QyBhTPv0GpYiKmqxVaaCTmPXEfw3e5r3f1gRgHJSelBVgDAlAAnoQdFUFOMiHJkkgVJBgSVggQiAgVClgTg4Kh74KSGYfVzgd65gGSbyRfrTChCQdSRVLlh0GhtREaeUEA+0K4/HGIHCXy6ChcYCUoeGB0YIGY3hF0pILkzohKnxecBEhq5ggCVghRfihfCihUj1UpnxD6+BMbBHAkSodJo3AlphAHuCZBAwMZzhMR8FhRyVDmDBHAkgf0XBIgMwAdpyLU72Gm8RR0d0HNLBh2F4cYE4F8hXiLF3iGyxAIpIeFE4fv+PuBaRyBCUaIkIgImONxAHwIkZKBG2CIqLxgfb54FZESEFojCcxwBFtYZD1YqDoS4pMhD0RBrx4mSRqIexwnqvMY1f6C10FHsjKHSjKIwHQIx6d4zJKFRTdErNSALPaADRKAzamHu7co2dKBHayIfd6IffiHYoUAAaMkgLMA970UrqdynTwTFrZGauoS7sIDGBRxoLg4SqYTEJMEi7aBUnsiUYk1WTJoaa948zEZCOQZApYZAqgpA0xBAM2VTKwY7CEJFeJhSOUpH05CILo5H8kjGUJ4J9sHRtQBCrsWYeGQhAGYODto+ZFwgyOTFCKYpKSYn5yHcmd3SB8IdV4JP/OIeUTqcKVkkFWAl0WkmCM9B2RUCWpLQlTdCVUzB0ZjkEbal3aMkEankFQzd4RmCXKGAmURl7VHlpYal9ioaXRCCYJqCXb9aXl9eTIGYRHjEZ56cOIqFVOzETl3IdGuEo/6AlLYkT8FESJ6GHyNcOWsUd1rdLI6IomNkVIZQof2IRDqiZEPMRIciTTokCjDlTWhJ8kCma6EAAg1eZKYEnmVkoNCETyGQSDACalzmag1GaK6GHKHKaGsJAfjITrpkRsKkSsvmLffd0HbgPXxEWqTFInWIXeKEAyakPALApEOQpeikQHTgr8uB9VTGeM9EpuQeCXCEvnuJ9v6KKCQEu/05RERoUoOVUjIlZm673nS74QfbZnubJE+nJF+zZKafyFQ6zFvI5DyT0oPgpAkK4nxLRnx+0AABaLE1RQAU6QlVhTh0JjE+Xky0oMCLDAOWCAMAiLN6HJaAxGKOxEK3hCjTKegAwAa/QGl+BjAfIESjaGIfoCiOBQ7NJmx8Xo+m4pEPqHzYKGzgaLCnRUwwSGj8KVUIKgURqpK6ApFQBI0QELk4aX1EqGVM6l1agZhjTgmzUplPELSa1IDIFpNShjlAFK1AHj6nSgldqLJChdh2lRC9apWkno0uap0zKiHwKLc7xp2QqAIJ6UOgEdVlxqEuaqM6xqL3XqCBGp1dppf8JSR3kEZwLxBE9tVWuYS/q+S/30SwXYhKuqn6hN6gt+S8F8A8GyQ8ikC8GmakHwSBcpJD7N5T0IKm9Cqv+Mat8sRAUcavvkKv5IQy8ioC+mkDEMigEQ6wHOCTIui/zYnzNyp1TGamJmhocMwCxKgINOY4ZoyH/EDEfEVYiQiIS8w7yKjHiaq/IeCJ9YTESUZHuoA+Ooq7IVCEPcFXuSgd2Kq0DqyH1qhG5iBX8ypT8ujG5KJ0Be5IEe0QDcbBVIZOWwbA7qLDj5BcOMrEVMpuq6pWIuQOFpwU36wRf+QM7mwU9KwU/6wNBiwVDywRF2wNHewVJCwVL+wdPqwRR6wf/U+uzOdsHV4sEVau1f1mEWcsHW3sEXSu2XwuIXHm2q5q2PelpI/e2cIsLJWexbhu3dnu3UKq2WSBxFLdeWdO3VmNxccC3gJtbf1u4piC43pFrFKa3EOa4Lga59SW5Ska5AGa5WIa5jkC4iPsJqta5q3YgjGsMsgW6pqtamnsIo/sLq+sHrTsJr5sKsdt3qWsIs2sJt5sHuesIuwu7tfsGvesHnLsJn/sJijsNwVsHyQuMdes7c/sNyzsH0fuuj+YQ0xsH1wutEva7tHsM2augFsa9Jie+bPC9kFq9k0W+a2C+youYY6sGw6sJxesJx2sH8Xs1h9teuOu+6psGIPdp//2rtM3bO88LCYI2pdgXwC7Hv4AQte/rc10mlbLLwH/gwAqclKskwZdgwQ1MwZQgZ0XmCvqXwKTrwYrZaB8sZenAG3N6wTaHwieMvikcwW/mwv1nwjAKw5IgaM7qjSVsJRpMvdu7vzq8wWUWxLqLw5HAwax7xDXcwUVswEpMxGnnCkYWiq47Y032xJXAxL4gZ1PGwlgcw0PcxVNsxjRsdlAsw7B7xjOcwVycxVH8CP9LcjYMwWycw3kcCfc7v51Qv0vsxuALY97AvkIcvmtcxthgyEk8x9qLyNnAyI9MyBUsyF98x9hrye3ryKyLyXBQx79TwLo7wE4jyr4wbHRzD/99nL/nBQirnLjYsGx7MyOS7L+eXAfTVgDVJrq3zDa9PAfbVgDdxsve+8tzMG48UstooMx8oG7JbMxCB81xEG8ygsrFZgnWXBv2diCy3GyW0M0tQzoyksu7XAnkXBv8JiPBPMyVsM61IXAygsy+IM8JpwTO7Av3XM9JQM2+wM/6nATbrAoB/c9GoG+/YNDHcL+nBciqkM6s62/MAMocZ8rGAM++YNE/TAQPTNBuULZ+ydHIG7YfzVcK/VgMXclFsNFPUNKnGwAnrXSknHEULQgenaA0HdN4qwszLZYaLc1Um2G9uRal4QoIKtQVi9JfoNIzUNM+vAhZpg+uICQvMrH/RFGLJKbUTcDUP4DVMaDVJOzUGUYmNhEdNwIUY5zIXcDVMODVzwrW0SqPGUNQIqAZumjTgcDWPKDWL4DXeh0FT+1kyLEaB5BCvAqmI03TIh0Efd0CWRbUW0fURbGXba0If517ZqovALAAgrR6do3WXLDYLPDUjyHVYUXVHGHVZ626YT0e+OoW5BQW/1TX+kgIdnqqIHp3OMBJh20GlR1UyjIQQcXZna3a9DAB/1ggO+QgI8Kr5LSToG0EY4gixDrCN/B2R43HDdgwsRgxcl2kb2GzPp0EfB3eQLB9mK0OycQROMGprvEAuOSjW7pLL9FA27nbL+x6gI1MikHYVWHY/8Ntu4nd1IidAqpkJqkh1LNCF6hBr90ET6VyoMfSogg628u82pZdAgap2Q4i3BRO2QHe4Xc9iuSSGgs0APsgMKnRT06IH1JKLi3+qLxt4biIFa7tn949F0NI3mT74V894P1IAgfxhiPlCqWKGmV1LrznUWuk5PZ9w8V93OQkSMtdev4N4ogw3rQt4iJJ5EXVCvuxFUYOVQLjDu26RTkF4/c9BM+d1Tw+2SFO4P/ILBnxVYhyIinSTxljIRR7QjWL5k7e04wg0Ru305NMAzdC3Yoc4ymt40bA0vLLyrA8CEUbJDvJyVsJ6BHN6H7d5nmt6QCA5Zk+wWCw5ikA6sUs6v8ONlN69yEIUD4hAap/5umCrnGEvsOe/gQ+iZ7AnX4BdB/kwYH8sEdIHAaOjr9b89IGfOtYy3bGqZpgB1B75CiIcjGNwRVBpuxdje0up+1LsHLxGZIASgLBEgGDohB8ERUQOyvXDozcjjbtLt5A1qOKoiKGJ39jjhE5ISrG3QCV3uQf9+4qB/A77gKZOqokoADGPQAFYECkgg7qOoDr3r3e8MqlgOyN7ALcSu8joE/k/tt72BhgFfHjC704vTS13p0vECKniVTNx34eD7FvgehWfnECv5aaTMZpXfOlrvObbulynNQ8fwLM3NE3r8deQOo7MPRt4MUAPupBbwJKX77/RY/yQO8GFE8KFl8ITK/1JZ/Tt3DyOtf1Ov30P7D1hFDs5QXpC030Pu/hQBzH5RD1a7vHUpzGqV3IZH8DZl/3cKzG5ZDNgT71xF3FQCHCdz8N4Bz4bZ8IYLzCVXbd03DOik/3dOzEfk8O7jz5WTLsjcDDnN8M9OzWfX/4vCv4qpDPor8CPTzzfJ/o3+DPqS98hc8npN/5pi/QBfA5tq8CYfz4ft76kGwPCB37KbD6Pd7Gi0+6EK35KmD8br7DYp8LYH/RrlP6yX8IV6+/A7f3pw7SI8D9pJv3Q0b54U8OaE87We+/t2/r5DDrMi3+n77+Swz/3c7pSJ8D7s800++7/+0PAgIwkqV5oikgBKr7wrE8o1Jw4znuOLqPS2jCIbFoJGIKygLn6HxCo7CASKpiWbPa4W3r/YJnlmXBEz6jn1Q0Nu2Wdt/yuZFC7tDz+vW5rf9PtQAOElaQbRAmfvGF+Skqxj1KumUoYUxiqlWdGBB4GpQgCAg8lBCAXglmAkauulppKFm80sowmhA0jB5EjDwcPDwsVCEUbKI41qYlLTUpPw9dKFFAV5fcmg6QDAMMEJCgDje4JFt7jS2Zma+rKFWwQ2OTEGiPJEysHCgglEwYHPBLUQ6eFDtL8BBMCMBBBoW15I2gV6LACAULDkzg94ABAAi9BKpyGMXQEkQi2f8F0HDSFUQAEu0dMKFA24IGAw6MA7lSSqUCl3aa23ABKKaWL/+VUoAKwgIA/kYA1EnUSawCs6ZizRrG6IQBN0t1tHlggYGNJDxK1Rptmtq2bjWxCfk2hru5du9OOfZlIN4TDPtCsfFjMOHChg8PDgJ4RMssfBczVgnZSIABoy5jzqx5M+fOnj0PkIu3sZXHkIVOpqz3lWm3pKW0Ti1byGtJsdVW/qx7t4DQs3/DfXZbq2DEO3oYz6EYOHMuq10NB96qOXUvtR9F/z3dbfHk3r9/X070uqLss7e3zc17Pfv2l31jbeyJQAISCeprQYDqhXnZ6HE/x5poKzVmjAAMDAD/igIKbBFBQPwNuFJ34BHGA4WHiZcJedhFKFKBJMzk0jczWWbPApZ9Q4Aw3kTEAAPfrDAAA/woUF9vM6Y1VQDIXdgjhT3QsmF5HTr0IQkNiCLCKQAwwOAB33DTWwIIjJNAA/ddCQFHCJTijZYAcJnjeEQ+8l+ZAUJHZkJGjuDNKAAk0JsuCMS0gghvAkARBFUIAIEC+gTkzZ/7pKKVmZIcmoiQifRXDZsANGDAKFaWMspLb+JJEZ5vEhCBLt2k6GmAjTqqpqKmshJgkmANod8JMDpB6jNsLtCLpXUOY8BTEdxZBUV0tomAqw9o482w9Zwg66yoDpIoIRD9Egw3Qzh4/wKyRyj7EJoFeHUAnyJcJKMIfyLY6wgU5eMtAL/cxI837EaFDLMozfuHs80+x+IICtaXAIMGnEjWCsR+VCOYCEKwQkUDLNAvgwAYTOwArJaQbZBo0hDOw15YHGS9e3w8B0QCAEoCixIxkPAD/BRQSsqgWqlfwhQpwEAn47xkbKT+ypvVoilcxEsjIZeqzL2ppmARRu6mSBMDD+CHrkRefnQukzAOgEDO9E0AAawmdMwSxpOEzRLRIp/txmshnlyPRRN8I3WxBOBptb7ebA0nydeSULaGY9uWttGCq034GRApNQJTTCalDYy85jlCBAnjnRPLHfViwDjA/kNffQagC/+24WJjO8DGIyCAH5gPCgtAJ54I4beGox9O+yLPQSCWwLkwrM3eCeZ5k8As7s0RRQAfAMwIDBzAPH0H3HR637YXBbgKNbtuQlcmP6Wr47p4qjoMshdF/SLma/FzCqH3gf6ZMyRw4sNeCSC+RVe2yY1FjtcDuQzkv2FCg7EQYjJkBQH+gIAY2oP16OIGAL5PBg04RZMAsIAFLIkET5tcm3IBgCfxb3nSI4f70qAe92wGPls4IQozo0KRNZBDPmsgAupBAI7UbV/4ABaoeiMAiRCgKw2oWgwgaMIYjq+E6hPTG5b4ByMqqoEvkUgOIdaVARSgPt7QXCdCeCAaQPFwSIT/0O1gU8K8yABgWZtB6uwDqwR843VfS+IMZ/CUPtnJBE+THOVgBcR6MCCGYdzKGElYxigMUgXkWUDC9gOD7Y1AAAXAGkVyIYDw/e+Mz4rhL8YCihzqigTA0pdLQug6fWQSHk5MlhILWag8XMdK+mOYw+gmk5rgRwAngtMCKtm/BibSXq7UQzCtM8yeGdOMDIzBP7xWs5u5ZAKB1OMDOGinGS2gGKUUYSrjc0w6FHOF3xTdIaEQThOQh0UvCtZLShBKHlrKK5EL4gCGOINzwhAa+LTCKsmZTERq0gXp/MbdPME3K3oli3lkkS9XwJFu6micctgnHKz3IEP+05wBVWQD/1mEFs1tk5p8zCMJGsokYG5UmPpMaUZdcFBkilOZsOxoHINWinbqUJQxyaFJ/zFCmI7HMi0cKlFfaI3rvJSV5XwCRQHQT3CyNA8I9BFVjWPAeGCMbgLQhQB+Or2lpsArSa1YVNEp0Tk0tTqqxBgcCfAkAlxUqS2NVVmvcdaJ1lWta7LeWMkKVmzllTF3fUNa9WoOpBaxlTKlw1PRGljDrqOxkVQsQJdZjcJCFquLTd9gm8pCooK2PUbNLHUkuwLKalQPU62qAqv6g6uSVjqdRS1TH3u+2OI2C6Y14m5tax3f5hYwny2qEoUa2t4AN33JDe5dVpuD1hYGtoFBDHQJI/9dejE3u1tZbiD6cjTtgpc23H3Bd3dS3vCil7zjFeh6m9je9N6FGUpwhtm8+174zgUdSlBHJuTLhLucF78CNogSEJIJ/ZZhLv6lr4Ab7AKSKMEkmSBwAQzcFgTz18EaRkFPfrIKCBdAwm2hsIU3bOIRVOUqruiwXUAs4hObWBoFoMYrUnwXFsM4x3kqwDteIWMaz8XGOobxX2pRF7v8eMgwTokyinyXIyt5w6h5iGTu4uQoY3kSUwZwlbPs5S+TYMtgHjOZy/yWCrg2zYPpMQmcq2bXXtXNb54zna1q5i9IgKvH3TNmGpCh4fKZz6N1qnEDbehDt3DQdw5MXwExgD//D3YvAzJtVjB7Ygk0+g+PNistBkJprFjaxJhexabt2ulJRxrU94XvqDNRahJ8egueTvVUQr3hVmPi1YI9NQpiTRRbaxjXk9C1U2mthVlDFtgOFnYa5+PIVZnCkTQgNmnaOscHjOJBneAYqp/QCVR8eyfKbjCzY2BJkn0kWsIghjGKQG2M+TACqARABF40ExhBYJJDwClQYS1RArR7BfpOBCkBu+gtlBsG7eQGKcOxVXdDmhxV6FzkwDECXTRFJhthwOd8+EldzNGvJ3gqPQ4ACq+MiH7rgpGKKlYRft2QYaDwxIJWEKcERMArYCEFw+DUgGkZ/OBZSPgL2nmPfBCK/wT+iJcQ3i1xEHFERlDTaShNMIAIGGBxUWrKn+jzSk47gR4Q8BMETgaKJhGrTRTb4gQY9Kv6LE4AE4iA2y2TgFJorj4FYFCTmhnyIYxbwER3AU7RpbSMrIsjaBmC06+wCYlknQENMDm9E7bHErTNKUoP6ddNHfYEJc8ALIpTPUVwJSuBrasHqqHrtAQ9klbcJTmHW8XfVHAjBB6/g1eB0esEIpqIJSdNj7jjQUREC5oeej+3etNib9LO+/sJVBSBNyiVR6ZYcx4uEr0CRHAACHQR9uj6BdNqT/2/A37V6d19Co6ivMR1pClP+WBcY9B4gRADfwkTIQ+rbrLm79ENuf+E7zFRsUnfteANroiA5kTKCYxFRzxJniiI72wCulzSKcVNJFEfxeCe+qEX+6EAPX2F4uhOWTwU5jAe8QmEWOCIBYmFCGTf5XXQNtWQVwSK6UDfrn0e5kEJ9EyTBR0fNyWA4dnELtUNuvyDjESgBYoAu9SW0A1dpunB/a0CsrkB/phD7rGaFOYBFWaCFaKBRbCDFq4fF9KBF2ICGKoVGX6gGc4BGpJNtxkWG4ZXubkKCVQLDdyH65wIXLkAAgQhHBrARQHivvnC1d1hCuShP4EdGhCMDBTikEDhAR3UIoJKEVVBzTGS7BHeQcFhJEYEF4aONliJARiAJVrL36khGJT/orThgg25YftMohSUm8HckOTVVIlAzMZpkd15gizVz8P0hsBIiox4ogqWAM8UI4IcIo74S28kDMB1lcJs1Q8ZDAIgCFjc4gT1mw72AchVAezQXPeBHD1AI+pkYyTdXFzMYhSUW/UdQAJQXARCztVlXVNc0CmMgt9JBOSkHeSEiNUh4zxoA0Bqw0YYQCnmwimc3iRdTtclADzKo0RSnFw1YhhAJBOuwNwtyJPA0QTlXQLEo+jFjd2xYzs+wTsSwOLpzCjsUuZtyvlt0wRcBkU8Bb91w0CGolPMnDYwwDBslUHNYOiYlJcIlWWwpCrK4Rm8hEbiyRTVg1GOQomwjyyi/6QTqCSeJOB8lN/0aeAlSsQkzUfF4SQchuVODoDXfELeEGVIuQkG/aJWKmWvGVsI1oNThiMsdpAuzYfeEZYH1qEnqkg9PImuBERX+s5H2F7zpSXqfNA3pJ1AXiRBPua6+M5DJSRbokJRekIDgklkRqBFeh5T1sNTREk41snW5AIqXM4DASZ4qSS9jUUE0slNyKREiGTWLOY2GQDzNA+YNM8uSeZoZgNw/mT/QE885g26zVNUjkhyloK8XcRcjlxdvko95I64wJ5XKEDe/MkIVuXQXCVWxuIbwGHg0GWyvaZ2geAU6mQcpuccrmd2tWcXvid6Vqd6jucR1OcZ3qcM5f+nfO6nEfTnG/6nJAboEaCfESxoCgyiVQ7oEOQZou2Zn6FToVFoaA3aU5UnCoyiDKALKEpahBIBmtWZmrHZCMjZiYLHVT2VCDxjYz4Ay5UCseCIGpGFNDJIJjJMFeTcxLiEMdTIv3gcnHRfY9IVibbjU1USSF4J9jCJAiBkKb7MygyhH1LElI6f6zQkXEnE1rmEk4oPEdChkgqXRHGmU2AJkwDlBC3A00RNSTGO1cjeANCe3GjeCOBD3gSdmQodk7rlN4zCnnSDWi7J22Sg3cBIlkYFQ+1kW/JpB/opFAJq3lgJ/nyR68CR5IhAAWwmvS2gpmTOEvbknApgpBZBmU6Xql1UqnMuT8bJ5k3ECfQAD3Mej1dEwPH4YASim0TU4BqhKpnO56q6hnU6ASqg3iCoKrEWayZQSbsQwrIyK4Do57SWma8BhbRaqzdV67aCGaBlaLiKK3J565itKIui64leV7mya7u667vCa7zK67zSa73a673ia77q677ya7/6678CbMAK7MASbMEa7MEibMIq7MIybJmFAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm proposed by the Antibody Working Group for the diagnosis of antibody-mediated rejection (AMR), if allograft dysfunction is present. A high risk setting (husband to wife or child to mother donor-recipient pairs, history of a sensitizing event (such as pregnancy, tranfusion, transplant), and knowledge of HLA-specific antibody (either present or historic) determines the predictive value of the various histologic and laboratory features, which are the major diagnostic modifiers. The presence of donor-specific antibody (DSA) is not essential for the diagnosis of AMR in a high-risk situation but can be diagnostic in the presence of C4d or histologic features of AMR even in a low-risk clinical setting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Montgomery, RA, et al. Transplantation 2004; 78:181.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34558=[""].join("\n");
var outline_f33_47_34558=null;
var title_f33_47_34559="Characteristics of NRTIs";
var content_f33_47_34559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic name (abbreviation)/trade name",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Formulations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elimination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum/intracellular half-lives",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse events",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Abacavir",
"        </strong>",
"        (ABC)/Ziagen",
"       </td>",
"       <td>",
"        Ziagen",
"        <hr/>",
"        <p>",
"         300 mg tablets",
"        </p>",
"        <p>",
"         20 mg/mL oral solution",
"        </p>",
"       </td>",
"       <td>",
"        Ziagen",
"        <hr/>",
"        <p>",
"         300 mg twice per day or",
"        </p>",
"        <p>",
"         600 mg once daily",
"        </p>",
"        <p>",
"         Take without regard to meals",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Metabolized by alcohol dehydrogenase and glucuronyl transferase",
"        </p>",
"        <p>",
"         Renal excretion of metabolites 82 percent",
"        </p>",
"        <p>",
"         Dosage adjustment for ABC recommended in patients with hepatic insufficiency",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        1.5 hrs/12-26 hrs",
"       </td>",
"       <td rowspan=\"4\">",
"        <ul>",
"         <li>",
"          <em>",
"           Hypersensitivity reactions (HSR):",
"          </em>",
"          Patients positive for HLA-B*5701 are at highest risk. HLA screening should be done prior to initiation of ABC. Rechallenge is not recommended.",
"         </li>",
"         <li>",
"          Symptoms of HSR may include fever, rash, nausea, vomiting, diarrhea, abdominal pain, malaise, or fatigue or respiratory symptoms such as sore throat, cough, or shortness of breath",
"         </li>",
"         <li>",
"          Some cohort studies suggest increased risk of myocardial infarction (MI) with recent or current use of ABC, but this risk is not substantiated in other studies",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Also available as:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         ABC with ZDV+3TC",
"        </p>",
"       </td>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         ABC 300 mg +",
"        </p>",
"        <p>",
"         ZDV 300 mg +",
"        </p>",
"        <p>",
"         3TC 150 mg",
"        </p>",
"       </td>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         1 tablet twice per day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epzicom",
"        <hr/>",
"        <p>",
"         ABC with 3TC",
"        </p>",
"       </td>",
"       <td>",
"        Epzicom",
"        <hr/>",
"        <p>",
"         ABC 600 mg +",
"        </p>",
"        <p>",
"         3TC 300 mg",
"        </p>",
"       </td>",
"       <td>",
"        Epzicom",
"        <hr/>",
"        <p>",
"         1 tablet once daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Didanosine",
"        </strong>",
"        (ddI)/Videx EC (generic available; dose same as Videx EC)",
"       </td>",
"       <td>",
"        Videx EC",
"        <hr/>",
"        <p>",
"         125, 200, 250, 400 mg capsules",
"        </p>",
"        <p>",
"         Buffered tablets (non-EC) no longer available",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         <strong>",
"          Body weight &ge;60kg:",
"         </strong>",
"        </p>",
"        <p>",
"         400 mg once daily",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <em>",
"         With TDF:",
"        </em>",
"        250 mg once daily",
"        <hr/>",
"        <p>",
"         <strong>",
"          Body weight &lt;60kg:",
"         </strong>",
"        </p>",
"        <p>",
"         250 mg once daily",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <em>",
"         With TDF:",
"        </em>",
"        200 mg once daily",
"        <hr/>",
"        <p>",
"         Take one-half hour before or 2 hours after a meal",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Renal excretion 50 percent",
"        </p>",
"        <p>",
"         Dosage adjustment in renal insufficiency recommended",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        1.5 hrs/&gt;20 hrs",
"       </td>",
"       <td rowspan=\"2\">",
"        <ul>",
"         <li>",
"          Pancreatitis",
"         </li>",
"         <li>",
"          Peripheral neuropathy",
"         </li>",
"         <li>",
"          Retinal changes, optic neuritis",
"         </li>",
"         <li>",
"          Lactic acidosis with hepatic steatosis +/- pancreatitis (rare but potentially life-threatening toxicity)",
"         </li>",
"         <li>",
"          Nausea, vomiting",
"         </li>",
"         <li>",
"          Potential association with noncirrhotic portal hypertension, some cases presented with esophageal varices",
"         </li>",
"         <li>",
"          One cohort study suggested increased risk of MI with recent or current use of ddI, but this risk is not substantiated in other studies",
"         </li>",
"         <li>",
"          Insulin resistance/diabetes mellitus",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Videx",
"        <hr/>",
"        <p>",
"         10 mg/mL oral solution",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Emtricitabine",
"        </strong>",
"        (FTC)/Emtriva",
"       </td>",
"       <td>",
"        Emtriva",
"        <hr/>",
"        <p>",
"         200 mg hard gelatin capsule",
"        </p>",
"        <p>",
"         10 mg/mL oral solution",
"        </p>",
"       </td>",
"       <td>",
"        Emtriva",
"        <hr/>",
"        <p>",
"         <em>",
"          Capsule:",
"         </em>",
"         200 mg once daily",
"        </p>",
"        <p>",
"         <em>",
"          Oral solution:",
"         </em>",
"         240 mg (24 mL) once daily",
"        </p>",
"        <p>",
"         Take without regard to meals",
"        </p>",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Renal excretion 86 percent",
"        </p>",
"        <p>",
"         Dosage adjustment in renal insufficiency recommended",
"        </p>",
"       </td>",
"       <td rowspan=\"5\">",
"        10 hrs/&gt;20 hrs",
"       </td>",
"       <td rowspan=\"5\">",
"        <ul>",
"         <li>",
"          Minimal toxicity",
"         </li>",
"         <li>",
"          Hyperpigmentation/skin discoloration",
"         </li>",
"         <li>",
"          Severe acute exacerbation of hepatitis may occur in HBV-coinfected patients who discontinue FTC",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Also available as:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atripla",
"        <hr/>",
"        <p>",
"         FTC with EFV+TDF",
"        </p>",
"       </td>",
"       <td>",
"        Atripla",
"        <hr/>",
"        <p>",
"         FTC 200 mg +",
"        </p>",
"        <p>",
"         EFV 600 mg +",
"        </p>",
"        <p>",
"         TDF 300 mg",
"        </p>",
"       </td>",
"       <td>",
"        Atripla",
"        <hr/>",
"        <p>",
"         1 tablet at or before bedtime",
"        </p>",
"        <p>",
"         Take on an empty stomach to reduce side effects",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Complera",
"         <hr/>",
"         FTC&nbsp;with TDF+RPV",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        Complera&nbsp;",
"        <hr/>",
"        <p>",
"         FTC 200 mg +",
"        </p>",
"        <p>",
"         TDF&nbsp;300 mg +",
"        </p>",
"        <p>",
"         RPV&nbsp;25 mg",
"        </p>",
"       </td>",
"       <td>",
"        Complera&nbsp;",
"        <hr/>",
"        <p>",
"         1 tablet daily with food",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Truvada",
"        <hr/>",
"        <p>",
"         FTC with TDF",
"        </p>",
"       </td>",
"       <td>",
"        Truvada",
"        <hr/>",
"        <p>",
"         FTC 200 mg +",
"        </p>",
"        <p>",
"         TDF 300 mg",
"        </p>",
"       </td>",
"       <td>",
"        Truvada",
"        <hr/>",
"        <p>",
"         1 tablet once daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Lamivudine",
"        </strong>",
"        (3TC)/Epivir",
"       </td>",
"       <td>",
"        Epivir",
"        <hr/>",
"        <p>",
"         150, 300 mg tablets",
"        </p>",
"        <p>",
"         10 mg/mL oral solution",
"        </p>",
"       </td>",
"       <td>",
"        Epivir",
"        <hr/>",
"        <p>",
"         150 mg twice per day or",
"        </p>",
"        <p>",
"         300 mg once daily",
"        </p>",
"        <p>",
"         Take without regard to meals",
"        </p>",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Renal excretion 70 percent",
"        </p>",
"        <p>",
"         Dosage adjustment in renal insufficiency recommended",
"        </p>",
"       </td>",
"       <td rowspan=\"5\">",
"        5-7 hrs/18-22 hrs",
"       </td>",
"       <td rowspan=\"5\">",
"        <ul>",
"         <li>",
"          Minimal toxicity",
"         </li>",
"         <li>",
"          Severe acute exacerbation of hepatitis may occur in HBV-coinfected patients who discontinue 3TC",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Also available as:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combivir",
"        <hr/>",
"        <p>",
"         3TC with ZDV",
"        </p>",
"       </td>",
"       <td>",
"        Combivir",
"        <hr/>",
"        <p>",
"         3TC 150 mg +",
"        </p>",
"        <p>",
"         ZDV 300 mg",
"        </p>",
"       </td>",
"       <td>",
"        Combivir",
"        <hr/>",
"        <p>",
"         1 tablet twice per day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epzicom",
"        <hr/>",
"        <p>",
"         3TC with ABC",
"        </p>",
"       </td>",
"       <td>",
"        Epzicom",
"        <hr/>",
"        <p>",
"         3TC 300 mg +",
"        </p>",
"        <p>",
"         ABC 600 mg",
"        </p>",
"       </td>",
"       <td>",
"        Epzicom",
"        <hr/>",
"        <p>",
"         1 tablet once daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         3TC with ZDV+ABC",
"        </p>",
"       </td>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         3TC 150 mg +",
"        </p>",
"        <p>",
"         ZDV 300 mg +",
"        </p>",
"        <p>",
"         ABC 300 mg",
"        </p>",
"       </td>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         1 tablet twice per day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Stavudine",
"        </strong>",
"        (d4T)/Zerit",
"       </td>",
"       <td>",
"        Zerit",
"        <hr/>",
"        <p>",
"         15, 20, 30, 40 mg capsules",
"        </p>",
"        <p>",
"         1 mg/mL oral solution",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Body weight &ge;60 kg:",
"         </strong>",
"        </p>",
"        40 mg twice per day",
"        <hr/>",
"        <p>",
"         <strong>",
"          Body weight &lt;60 kg:",
"         </strong>",
"        </p>",
"        30 mg twice per day",
"        <sup>",
"         &sect;",
"        </sup>",
"        <hr/>",
"        <p>",
"         Take without regard to meals",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Renal excretion 50 percent",
"        </p>",
"        <p>",
"         Dosage adjustment in renal insufficiency recommended",
"        </p>",
"       </td>",
"       <td>",
"        1 hr/7.5 hrs",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Peripheral neuropathy",
"         </li>",
"         <li>",
"          Lipoatrophy",
"         </li>",
"         <li>",
"          Pancreatitis",
"         </li>",
"         <li>",
"          Lactic acidosis/severe hepatomegaly with hepatic steatosis (rare but potentially life-threatening toxicity)",
"         </li>",
"         <li>",
"          Hyperlipidemia",
"         </li>",
"         <li>",
"          Insulin resistance/diabetes mellitus",
"         </li>",
"         <li>",
"          Rapidly progressive ascending neuromuscular weakness (rare)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Tenofovir",
"        </strong>",
"        (TDF)/Viread",
"       </td>",
"       <td>",
"        Viread",
"        <hr/>",
"        <p>",
"         300 mg tablet",
"        </p>",
"       </td>",
"       <td>",
"        Viread",
"        <hr/>",
"        <p>",
"         1 tablet once daily",
"        </p>",
"        <p>",
"         Take without regard to meals",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Renal excretion",
"        </p>",
"        <p>",
"         Dosage adjustment in renal insufficiency recommended",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        17 hrs/&gt;60 hrs",
"       </td>",
"       <td rowspan=\"4\">",
"        <ul>",
"         <li>",
"          Renal insufficiency, Fanconi syndrome",
"         </li>",
"         <li>",
"          Osteomalacia",
"         </li>",
"         <li>",
"          Potential decrease in bone mineral density",
"         </li>",
"         <li>",
"          Severe acute exacerbation of hepatitis may occur in HBV-coinfected patients who discontinue TDF",
"         </li>",
"         <li>",
"          Asthenia, headache, diarrhea, nausea, vomiting, and flatulence",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Also available as:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atripla",
"        <hr/>",
"        <p>",
"         TDF with EFV+FTC",
"        </p>",
"       </td>",
"       <td>",
"        Atripla",
"        <hr/>",
"        <p>",
"         TDF 300 mg +",
"        </p>",
"        <p>",
"         EFV 600 mg +",
"        </p>",
"        <p>",
"         FTC 200 mg",
"        </p>",
"       </td>",
"       <td>",
"        Atripla",
"        <hr/>",
"        <p>",
"         1 tablet at or before bedtime",
"        </p>",
"        <p>",
"         Take on an empty stomach to reduce side effects",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Truvada",
"        <hr/>",
"        <p>",
"         TDF with FTC",
"        </p>",
"       </td>",
"       <td>",
"        Truvada",
"        <hr/>",
"        <p>",
"         TDF 300 mg +",
"        </p>",
"        <p>",
"         FTC 200 mg",
"        </p>",
"       </td>",
"       <td>",
"        Truvada",
"        <hr/>",
"        <p>",
"         1 tablet once daily",
"        </p>",
"        <p>",
"         Take without regard to meals",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Zidovudine",
"        </strong>",
"        (ZDV)/Retrovir (generic available; dose same as retrovir)",
"       </td>",
"       <td>",
"        Retrovir",
"        <hr/>",
"        <p>",
"         100 mg capsules",
"        </p>",
"        <p>",
"         300 mg tablets",
"        </p>",
"        <p>",
"         10 mg/mL intravenous solution",
"        </p>",
"        <p>",
"         10 mg/mL oral solution",
"        </p>",
"       </td>",
"       <td>",
"        Retrovir",
"        <hr/>",
"        <p>",
"         300 mg twice per day or",
"        </p>",
"        <p>",
"         200 mg three times per day",
"        </p>",
"        <p>",
"         Take without regard to meals",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Metabolized to GAZT",
"        </p>",
"        <p>",
"         Renal excretion of GAZT",
"        </p>",
"        <p>",
"         Dosage adjustment in renal insufficiency recommended",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        1.1 hrs/7 hrs",
"       </td>",
"       <td rowspan=\"4\">",
"        <ul>",
"         <li>",
"          Bone marrow suppression: macrocytic anemia or neutropenia",
"         </li>",
"         <li>",
"          Nausea, vomiting, headache, insomnia, asthenia",
"         </li>",
"         <li>",
"          Nail pigmentation",
"         </li>",
"         <li>",
"          Lactic acidosis/severe hepatomegaly with hepatic steatosis (rare but potentially life-threatening toxicity)",
"         </li>",
"         <li>",
"          Hyperlipidemia",
"         </li>",
"         <li>",
"          Insulin resistance/diabetes mellitus",
"         </li>",
"         <li>",
"          Lipoatrophy",
"         </li>",
"         <li>",
"          Myopathy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Also available as:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combivir",
"        <hr/>",
"        <p>",
"         ZDV with 3TC",
"        </p>",
"       </td>",
"       <td>",
"        Combivir",
"        <hr/>",
"        <p>",
"         ZDV 300 mg +",
"        </p>",
"        <p>",
"         3TC 150 mg",
"        </p>",
"       </td>",
"       <td>",
"        Combivir",
"        <hr/>",
"        <p>",
"         1 tablet twice per day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         ZDV with 3TC+ABC",
"        </p>",
"       </td>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         ZDV 300 mg +",
"        </p>",
"        <p>",
"         3TC 150 mg +",
"        </p>",
"        <p>",
"         ABC 300 mg",
"        </p>",
"       </td>",
"       <td>",
"        Trizivir",
"        <hr/>",
"        <p>",
"         1 tablet twice per day",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ABC: abacavir; ddI: didanosine; FTC: emtricitabine; 3TC: lamivudine; d4T: stavudine; TDF: tenofovir; RPV: rilpivirine; ZDV: zidovudine; GAZT: glucuronidated metabolite of zidovudine (glucuronylazidothymidine).",
"    <div class=\"footnotes\">",
"     &Delta; Trade names shown may be specific to the United States.",
"     <br>",
"      <font class=\"lozenge\">",
"       &loz;",
"      </font>",
"      Preferred dosing with oral solution is twice per day (total daily dose divided into 2 doses).",
"      <br>",
"       &sect; WHO recommends 30 mg twice per day dosing regardless of body weight.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated January 10, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_47_34559=[""].join("\n");
var outline_f33_47_34559=null;
